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8I INTRODUCTION
Infertility, defined as failure to conceive within 1 year of normal cohabitation, occurs in approximately
10-20% of couples (Barbieri, 1999a). The main cause of female infertility is anovulation. Thus the
introduction of the ovulation inducers clomiphene citrate (CC) and gonadotrophins after the mid-
1960ies brought about a revolution in the treatment of infertility.  The next breakthroughs in infertility
treatment were the development of various assisted reproductive technologies (ART): in vitro
fertilization (IVF) – embryo transfer (ET) technique (Edwards et al., 1969; Steptoe and Edwards,
1978), cryopreservation techniques (Trounson and Mohr, 1983), ovum donation programmes (Lutjen et
al., 1984) and intracytoplasmic sperm injection (ICSI) (Palermo et al., 1992). At present, almost 80%
of couples complaining of infertility can be helped to achieve a child.
Initially, the ovulation inducers and high technology infertility treatments were thought to be
specific and not to cause any marked untoward side effects.  Therefore, reports on a possible
association between infertility treatment and ovarian cancer in the early 1990ies caused great concern
(Whittemore et al., 1992; Willemsen et al., 1993; Rossing et al., 1994). Theoretically, infertility
treatments may trigger the development of ovarian cancer by causing multiple traumata on the ovarian
surface (Fathalla, 1971; Casagrande et al., 1979) and/or by inducing abnormally high levels of
gonadotrophins (Stadel, 1975) and oestrogens (Cramer and Welch, 1983). The data linking infertility
treatment to genital cancer were weakened by the knowledge that nulliparity itself is a risk factor for
cancer of the ovary, breast and endometrium (Kvale et al., 1991), and this aspect had not always been
adequately considered in the first epidemiological studies.  In the context of using gonadotrophins, the
ovarian granulosa cell tumour (GCT) attracts special interest, for in rodents, this tumour develops in the
presence of high concentrations of gonadotrophins (Biskind et al., 1952; Tennent et al., 1990; Risma et
al., 1995). Hence reports of its occurrence in infertile women (Willemsen et al., 1993; Rossing et al.,
1994; Unkila-Kallio et al., 1997) might imply an association with infertility treatments.  Thus, the GCT
could serve as a model for assessing the risks of ovulation inducers.
This study was conducted to elucidate the impact of infertility and of its treatment on the
occurrence of GCT, and the influence of an IVF programme on factors that may be of relevance for the
formation and detection of a tumour.
9II REVIEW OF THE LITERATURE
1. INFERTILITY
A woman (a couple) is said to be infertile if pregnancy is not achieved within 12 months despite regular
intercourse (Barbieri, 1999a). One-third of cases of infertility are related to female factors, one-third to
male factors, and one-third to a combination of the two.  The most common cause of infertility is
anovulation, followed by male factors and tubal occlusion / abnormalities (Table 1).  However, in spite
of thorough examinations, the cause of infertility still remains unexplained in approximately 10-20% of
infertile couples (Collins, 1995).
Eighteen years ago the prevalence of infertility in females between 25 and 45 years of age in
Finland was 17% (Rantala and Koskimies, 1986). This is in close accord with the infertility rate of 13%
in women between 15 to 44 years of age in the USA (Mosher and Pratt, 1987). Thus, infertility was one
of the most common gynaecological disorders, and it now seems to be increasing (Stephen and
Chandra, 1998).  This increase may be a due to postponement of childbearing beyond the most fertile
years and, indeed, in Finland the mean age at the first delivery has increased from 24.6 years in 1965 to
27.6 years in 1995 (personal communication, M Gissler, Finnish Birth Register). The age of the female
(and the oocytes) has a great impact on female fertility: in the Hutterites, a Swiss colony in Canada
among whom contraception is not used, infertility occurred in 11% of women after the age of  34, in
33% by the age of 40 and in 87% at the age 45, the rate of primary infertility being low (2.4%) (Tietze,
1957).  The western lifestyle and standard of living may nowadays impair fertility not only in the
female, but also in the male, because, at least in some countries, sperm quality has deteriorated
(Andersen et al., 2000; Jensen et al., 2000).  Thus it is likely that in future demands for treatment of
infertility will increase.
Table 1.  Causes of infertility based on a meta-analysis of 21 publications and 14 141 infertile couples
(Collins, 1995).
                                                             
Cause of infertility                            %        
Anovulation 27
Tubal factor 22
Endometriosis    5
Uterine / cervical factor   4
Male factor 25
Unexplained                                      17        
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2. TREATMENT OF INFERTILITY
The choice of treatment depends on the age of the patient, the cause of infertility and duration of the
infertility, the severity of endometriosis, the results of prior treatments and the wishes of the couple
(Crosignani and Rubin, 2000). The couple is informed about the timing of intercourse (Wilcox et al.,
1995) and, as general health measures, the debilitating effects on fertility of both smoking (Rantala and
Koskimies, 1987; Zinaman et al., 2000) and female overweight (Clark et al., 1998; Silva et al., 1999).
In addition, hyperprolactinaemia and disorders of the thyroid should be treated appropriately (Arojoki
et al., 2000). As regards the infertility itself, surgery is usually recommended if the cause is
endometriosis (Marcoux et al., 1997), uterine abnormalities, ovarian tumours, or resistant anovulation
in patients with the polycystic ovary syndrome (PCOS) (Tiitinen et al., 1993a; Anttila et al., 1998;
Tulandi and al Took, 1998). For example, in patients with PCOS, the cumulative rate of conception
within 12 months after ovarian drilling with diathermy exceeded 50%, and, if the pre-operative
luteinizing hormone (LH) level was above 10 IU/L, was even 89% (Li et al., 1998).
The most effective treatment for all types of infertility is assisted reproduction in the form of
IVF or ICSI (Hull, 1994; Forti and Krausz, 1998).  Both treatments require the use of drugs that induce
multiple ovulation. In clinical practice, therefore, not only patients with anovulatory infertility but also
infertile patients with ovulatory cycles are exposed to ovulation inducers (Donderwinkel et al., 2000).
2.1. Induction of ovulation
The majority of cases of female infertility are caused either by anovulation or by various aberrations in
ovulation (Crosignani et al., 1999; Yen, 1999a; Yen and Laughlin, 1999b) (Tables 1 and 2). The
majority of ovulatory disorders are due either to derangement of ovarian function (45%, e.g. PCOS and
premature ovarian failure) or to hypothalamic dysfunction (38%, mainly weight loss, exercise, stress);
the minority (17%) are caused by pituitary disease (Barbieri, 1999a).  Thus, for these patients, the
introduction of ovulation inducers in the1960ies was a major breakthrough.
2.1.1. Physiology and principles of induction of ovulation
Ovulation is a complex process, involving a cyclic cascade of neuroendocrine signals, pituitary
hormones and ovarian steroid and protein hormones.  In addition, to guarantee the success of ovulation,
a number of autocrine and paracrine regulators function both in the pituitary and in the ovaries (Figure
1 and Table 3) (Büscher et al., 1999; Nash et al., 1999; Hull and Harvey, 2000).  Follicular growth
before the preantral stage is independent of gonadotrophins (Aittomäki et al., 1996), but the selection
of a cohort of follicles in the early stage of a given menstrual cycle and the final selection of the
dominant follicle are highly dependent on follicle-stimulating hormone (FSH) (Figures 1 and 2).  The
secretion of FSH and LH from pituitary gonadotrophes is caused by the pulsatile secretion of
gonadotrophin-releasing hormone (GnRH) from the hypothalamus and, as a result, the FSH and LH
secretions are also pulsatile.  FSH enhances oestrogen production from the granulosa cells by
stimulating aromatase activity in these cells. It also regulates the development and number of its own
receptors on the granulosa cells, and induces the formation of LH receptors on the theca cells. LH, in
turn, induces the production of androgens from cholesterol in the theca cells, and these androgens are
then converted into oestrogens through aromatization in the granulosa cells (Figure 2). Thus, both FSH
and LH action contribute to oestrogenicity during the menstrual cycle. (Yeh and Adashi, 1999)
Oestrogen and inhibin regulate the FSH secretion of the pituitary by negative feedback.
Oestrogen also affects its own production by increasing aromatase activity or by inhibiting androgen
production. The oestrogen peak in the blood that precedes ovulation is followed by an LH surge, which
triggers ovulation approximately 36 hours later.  However, the exact mechanism of ovulation is not
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well understood (Büscher et al., 1999). the follicular fluid surrounding the cumulus oophorus contains
leucocytes and a great number of local auto- and paracrine regulators (Table 3), of which at least
prostaglandins, angiotensin II, plasmin and interleukins seem to be necessary for ovulation (Anttila et
al., 1998; Büscher et al., 1999). After ovulation, the oestrogen levels fall when the granulosa cells
become luteinized and vascularized and start producing progesterone under the control by LH (Yeh and
Adashi, 1999; Geva and Jaffe, 2000).
In anovulatory patients ovulation is induced artificially by administration of either CC or
gonadotrophins, which increase the levels of FSH, the aim being to induce the growth of one to two
follicles (Crosignani et al., 1999).  In hypergonadotrophic hypogonadism induction of ovulation does
not succeed because, in this condition, endogenous FSH is already high. Treatment of infertile women
with regular periods with ovulation inducers (i.e. women with unexplained infertility, minimal
endometriosis or sometimes mild male factor infertility) is based on the assumption that ovulation
inducers lead to the development of one or several follicles with improvement of ovarian and
endometrial endocrine environment and so increase the likelihood that at least one follicle will lead to
ovulation, conception and pregnancy.  This treatment carries an increased risk of multiple pregnancy if
two or more ova become fertilized (Isaksson and Tiitinen, 1997; Forti and  Krausz, 1998; Hughes et al.,
2000b). In assisted reproduction (See 2.2.1) high doses of ovulation inducers are administered after
pituitary down-regulation in order to achieve multiple mature oocytes.  This ovarian stimulation is
called controlled ovarian hyperstimulation, and is used at present for treatment of all types of infertility
(Forti and  Krausz, 1998).
2.1.2. Clomiphene citrate
The capacity of CC to induce ovulation was demonstrated in 1961 (Greenblatt et al., 1961).  This
perorally administered drug is a non-steroidal oestrogen agonist/antagonist synthesized in 1956 (Table
4). It blocks hypothalamic oestrogen receptors and thus creates a hypo-oestrogenic state in the
hypothalamus. This leads to an increase in the pulse frequency of GnRH, which in turn increases FSH
and LH secretion, leading finally to the growth of one or several follicles (Barbieri, 1999a).
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Table 2.  Aetiology of anovulation and its relation to gonadotrophin and oestradiol levels
(Yen, 1999a; Yen, 1999b).
                                                                                                                                                            
Cause of anovulation                                                                     FSH      LH        E2                     
Hypothalamic 
GnRH deficiency ↓ ↓ ↓
Idiopathic
Kallmann´s syndrome
GnRH receptor gene mutations N N ↓
Dysfunction of pulsatile GnRH secretion N/↓ N/↓ ↓
Puberty, lactation
Weight loss, exercise, stress
Tumours of the hypothalamic area:
craniopharyngeoma, germinoma,
histiocytosis, sarcoidosis, lymphoma
haemochromatosis,
Wegener´s granulomatosis
Head injury
Irradiation (head, neck)
Pituitary 
Defect of the gonadotrophs ↓ ↓ ↓
Pituitary surgery
Pituitary necrosis / interruption of vascularity
Sheehan´s syndrome
Pituitary apoplexy
Dysfunction of the gonadotrophes
Empty sella syndrome ↓ ↓ N/↓
Lymphocytic hypophysitis, autoimmune ↓ ↓ N/↓
Pituitary adenomas and tumours ↑/N/↓ ↑/N/↓ N/↓
Ovarian 
Ovarian failure ↑ ↑ ↓
Genetic, autoimmune, cytotoxic
chemotherapy, irradiation (pelvic)
Inappropriate ovarian-pituitary feedback
Use of oral contraceptives ↓ ↓ N
Use of constant doses of oestrogen ↓ ↓ N
Excess of functional oestrogens and androgens ↓ ↓ ↑
Androgen or oestrogen-producing tumour ↓ ↓ ↑
Aromatase excess and deficiency syndromes ↓/↑ ↓/↑ ↑/↓
Gene mutations of FSH, LH, and oestrogen receptors ↑ ↑ N/↓
Inappropriate  feedback secondary to combined central-peripheral dysfunctions
Polycystic ovary syndrome N N/↑ N/↑
Cushing´s syndrome N N N
Thyroid hormone disorders N N N
Excess of prolactin or growth hormone                                        N          N          N/↓                   
N: normal level; ↑ : elevated level;  ↓ : decreased level;
E2: oestradiol; FSH: follicle-stimulating hormone; GnRH: gonadotrophin-releasing hormone;
LH: luteinizing hormone
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Figure 1. Regulation of ovarian function. 
FSH: follicle-stimulating hormone; GnRH: gonadotrophin-releasing hormone; LH: luteinizing hormone; 
TSH: thyroid-stimulating hormone
Figure 2.  The two-cell / two-gonadotrophin hypothesis of follicular oestrogen production.
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Table 3. Some endocrine and paracrine ovarian regulators and their effects in the ovary and
on ovarian tumour growth in vitro (Büscher et al., 1999, Nash et al., 1999; Yeh and Adashi, 1999;
Doraiswamy et al, 2000).
                                                                                                                                                                                                   
Putative effects in the Putative effect on the growth
                                                                 ovary                                                                     of ovarian tumours                    
Steroids 
 Oestradiol proliferation of Gcells, antiatretic effect modulated by cytokines
 Growth hormone modulates follicular growth
 Progesterone inhibits Gcell apoptosis concentration-dependent effect
 Testosterone and other androgens substrates for oestrogen synthesis
promote progesterone synthesis,
induce atresia (high concentration)
Peptides
 Basic fibroblast growth factor AGF, mitogenic, prevents atresia, AGF, increased serum levels
progesterone production
 Epidermal growth factor inhibits differentiation of Gcells stimulates
  Transforming growth factor α AGF, inhibits Gcell proliferation
 IGF1 AGF, prevents atresia
 IGF 2 regulation of corpus luteum
 Leptin AGF, regulates IGF-mediated effects ?
 TGF β AGF, modulates the effect of inhibins AGF, inhibitis epithelial / stimulates
and activins, post-ovulatory healing, mesenchymal cell growth, immunoinhibition,
prevents atresia TGFβ2 conditions precancerous epithelial cells?
   Activin stimulates FSH secretion
   Follistatin binds to activin
   Inhibin suppresses FSH secretion
 Vascular endothelial growth factor AGF, vascular permeability AGF
Cytokines of leucocyte origin
IL-1 follicle growth, suppresses premature stimulates, induces IL-6 secretion
luteinization,  inhibits progesterone secretion
 IL-2 facilitatates cell mediated immunity ?
 IL-6  reduces FSH binding capacity, stimulates, cell attachment and migration
postovulatory healing inhibits , apoptosis, increased serum levels
 IL-8 targets leucocytes, upregulated by TGF-β? AGF, stimulates,  migration of lymphocytes
 Tumour necrosis factor α AGF, inhibits progesterone secretion stimulates, induces IL-6 secretion
regression of CL?,stimulated by FSH
induces atresia
 Granulocyte-macrophage stimulates, overcomes some effects of TGFβ
 colony-stimulating factor AGF increased serum levels
Other Substances
 Corticotrophin-releasing factor regulates thecal-stromal cells
 Plasminogen activator ovulation ?
 Prostaglandins ovulation ?
 Renin / Angiotensin II                           ovulation?                                                                                                                             
AGF: angiogenetic factor; CL: corpus luteum; FSH: follicle-stimulating hormone; G cell: granulosa cell; IGF: insulin-like growth
factor; IL: interleucin; TGFβ: transforming growth factor β
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In the presence of normal or moderately elevated gonadotrophin levels, as seen, for
example, in women with PCOS, the drug of choice for treatment of anovulation is CC (Hughes et al.,
2000a).  In the presence of hyper- or hypogonadotrophic hypo-oestrogenism, CC fails to cause
ovulation because of lack of oestrogen feedback from the hypothalamus and hypophysis. The dose of
CC can be adjusted to the ovarian response, and ovulation occurs approximately 5 to 12 days after the
last dose of CC.  The starting dose is 50 to 100 mg/day for 5 days, beginning on the third, fourth or
fifth cycle day, but the dose can be increased to 200 mg/day depending on the ovarian response. The
half-life of CC is approximately 5 days. (Barbieri, 1999a)
With a daily dose of 50 mg of CC, approximately 50% of anovulatory women will ovulate.  An
additional 25% of patients can be induced to ovulate by increasing the dose of CC to 100 mg daily. If
ovulation occurs after CC intake, the conception rate may be as high as 25% per cycle in the first few
cycles, but this tends to decline after the first 3 to 6 months of treatment (Barbieri, 1999a). Thus CC
treatment is recommended to be given during four to six consecutive cycles (Tiitinen et.al, 1993b;
Isaksson and Tiitinen, 1997).  It is known that, apart from the ovulation following CC intake, the
cervical mucus may not be optimal and the endometrium may remain thinner than 7 mm, factors that
are both associated with a poor implantation rate. In addition, following CC intake, the histology of the
endometrium in the luteal phase shows a reduction in glandular density (Sereepapong et al., 2000),
vasomotor flushes are frequent and the risk of multiple pregnancy is increased (Table 6).
Another antioestrogen, tamoxifen, can also be used for induction of ovulation. It is given at 20
to 40 mg/day for 5 days, beginning on day 3 of the cycle (Borenstein et al., 1989).  In some countries,
tamoxifen is used if CC fails to induce ovulation, but in Finland the next step after CC failure is usually
the use of gonadotrophins.  Continuous use of tamoxifen is known to associate with increased risk of
endometrial cancer and, although the annual risk is low, 2/1000 tamoxifen treated women, tamoxifen is
classified as an endometrial carcinogen (Cardosi and Fiorica, 2000; Marttunen et al., 2001).  There
have also been some other antioestrogens on the market, e.g. cyclofenil, but their efficacy for inducing
ovulation has not been established (Hughes et al., 2000a).
2.1.3. Gonadotrophins
Commercially available gonadotrophin preparations contain injectable FSH and human chorionic
gonadotrophin (hCG); the latter is used as an LH substitute.  These glycoprotein hormones contain a
common α-subunit and a hormone-specific β-unit that dictates their biological specificity (Halvorson
and Chin, 1999) (Figure 3).
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Figure 3. Structures of the common α-glycoprotein hormone (GPHα), the follicle-stimulating 
hormone (FSH), luteinizing hormone (LH), and human chorionic gonadotrophin (hCG).  
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Table 4.  Drugs used for induction of ovulation and in assisted reproduction in Finland.
                                                                                                                                         
Generic name, Introduction Usual dosage                                                            
Route of to Finland Ovulation induction Superovulation for ART
administration                                         Dose/ day (range)             Dose/ day (range)                  
Anti-oestrogens
 clomiphene citrate, p.o. 1966 100 (50-250) mg 150mg (100-250mg)
Gonadotrophins
 hCG 1958
 urinary hCG i.m./ s.c. 1966 5000 IU 5000 IU or 10 000 IU
 FSH
 human menopausal 1966 75-225 IU 150 (75-450) IU
 urinary, i.m. 
 highly purified, s.c. 1994 75-225 IU 150 (75-450) IU
 recombinant, s.c. 1997 37.5-100 IU 150 (50-450) IU
GnRH agonists late 1980s
 
buserelin, nasal spray 1.2 (0.6-1.2) mg
 nafarelin, nasal spray 0.8 (0.4-0.8) mg 
 goserelin, s.c. implant 3.6 mg / 4 weeks 
 leuprorelin, s.c. 3.75 mg / 4 weeks
 triptorelin, i.m. 3.75 mg / 4 weeks
GnRH antagonists 1999
 cetrorelix, s.c. 0.25 mg
 ganirelix, s.c.                                                                             0.25 m g                               
ART: assisted reproductive technologies; FSH: follicle-stimulating hormone; GnRH: gonadotrophin-releasing 
hormone; hCG: human chorionic gonadotrophin; i.m.: intra-muscular; OI: ovulation induction; p.o.: per os;  
s.c.: subcutaneous 
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Gonadotrophins were first used for induction of ovulation in 1958, with FSH isolated from pituitary
extract (Gemzell et al., 1958) (Table 4).  Then, in the early 1960ies, FSH isolated from the urine of
postmenopausal women proved to cause ovulation (Lunenfeld et al., 1962).  In addition to FSH and LH
these early preparations also contained large amounts of urinary proteins, cytokines, growth factors,
transferrins and other factors that could modulate ovarian function (Gast, 1995).  In the 1990ies, highly
purified urine preparations containing significantly more FSH than LH became available. However,
even such purified preparations contained enough urinary proteins to cause allergic reactions in some
patients (Odink et al., 1995; Albano et al., 1996).  These proteins were then eliminated by purifying the
urine with the help of FSH monoclonal antibodies and the subsequent preparations contained
approximately 95% of FSH.  The latest progress in this field was the development of recombinant FSH
in the late 1990ies, when it was found possible to produce pure FSH containing no LH or other
proteins. This preparation is suitable for subcutaneous administration, making self-administration
possible (Shoham and Insler, 1996; Tulppala et al., 1999) (Table 4).  Gonadotrophins are used for
induction of ovulation in the following groups of patients:
a) with hypogonadotrophic hypo-oestrogenic anovulation
   (treatment with a preparation containing both FSH and LH)
b) with polycystic ovaries if CC has failed (treatment with a pure FSH preparation)
c) with unexplained infertility, mild endometriosis or mild male factor infertility
(treatment with either preparation)
d) undergoing controlled ovarian hyperstimulation for IVF or other ART.  (The
preparation is chosen according to the cause of infertility and the prior response to
ovarian stimulation.)
Induction of ovulation with gonadotrophins should be carefully monitored by assessments of
the serum oestradiol (E2) level and of the growth of both follicles and endometrium. At present, the
programme most commonly used is the one with low-dose FSH or FSH/LH.  In this programme, FSH
is initiated with a daily dose of 50-150 IU, and the dosage is adjusted after 6 or 7 days, according to the
ovarian and endometrial response.  When the serum E2 is between 0.6 – 0.9 nmol/L / follicle and the
diameter of the largest follicle is in the range of 16 to 18 mm, 5000 IU of hCG is administered to
mimic the LH surge and cause rupture of the follicle, with ovulation approximately 36 hours later
(Barbieri, 1999a). Another possibility is the step-down programme, which starts with a high dose of
FSH (150-300 IU) for 3 to 4 days for the selection of follicles, after which the dose is reduced to
maintain follicular development (Fauser et al., 1993).  Either of these regimens can be used for
induction of ovulation in patients with PCOS or for lean young women who are prone to develop the
ovarian hyperstimulation syndrome (OHSS, See 3.1). The most common adverse effects of the use of
gonadotrophins are this syndrome and multiple pregnancy (Table 6).
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2.1.4. Gonadotrophin-releasing hormone
Native GnRH is essential for normal ovulation.  Synthetic native-like GnRH is available and can be
given intravenously in a pulsatile fashion (14 µg per pulse every 90 min) to induce the growth of one
follicle (Filicori et al., 1994; Bayram et al., 2000). The half-life of this GnRH is short, from 2 to 4
minutes, and thus its administration is demanding and very expensive. Therefore it is not used in
clinics, at least in Finland.
By replacing one amino acid (glycine) of the native GnRH with the unnatural D-amino acid and
ethylamide groups, GnRH agonists have been produced which have 2.5 times longer half-lives and are
up to 200 times more effective in releasing gonadotrophins from the pituitary than native GnRH.
Administration of GnRH agonists causes an initial increase in LH and FSH secretion (“agonistic, flare-
up phase”) but, if this is  continued at the same dosage for several days, desensitization of the pituitary
GnRH receptors ensues, and results in suppression of FSH and LH secretion (“antagonistic phase”) and
in hypo-oestrogenism.  These GnRH agonists have gained wide clinical use (Table 4) not only in
reproductive medicine but also in the treatment of endometriosis, fibroids and hormone-dependent
tumours.
GnRH agonists can be used in combination with induction of ovulation to avoid premature
luteinization of the developing follicles (Homburg et al., 1993).  With the aid of GnRH agonists, it is
possible to time ovarian stimulation and ovulation or oocyte retrieval better than is the case with the
natural LH surge. It has been shown that the use of the GnRH agonist in IVF / ICSI cycles improves
the outcome of treatment (Hughes et al., 1992). With the use of the GnRH agonist, side-effects are
infrequent and mild (Tapanainen et al., 1993) though OHSS may be a more frequent phenomenon than
on stimulation without the GnRH agonist (Table 6).
A further modification of the GnRH molecule has resulted in the development of GnRH
antagonists that totally abolish the effect of GnRH.  These GnRH antagonists block pituitary function
rapidly without any flare-up phenomenon and may therefore be used in IVF programmes to prevent the
LH surge (Bouchard and Fauser, 2000; Devroey, 2000).
2.2. Assisted reproduction technologies
In ART (Table 5), the oocytes and/or sperms are handled outside the body and then transferred into the
female body. To guarantee the availability of an embryo for transfer, an attempt is made to cause
several oocytes to mature with the help of ovulation inducers. The most conspicuous progress in ART
has been made by the use of the GnRH agonist, transvaginal ultrasound (Wikland et al., 1989),
cryopreservation techniques (Trounson and  Mohr, 1983; Tiitinen et al., 1995), and ICSI (Palermo et
al., 1992).  The major factor predicting the outcome of ART is advancing age of the female: in women
over 38 years old, ART results in deliveries in 11%, while in younger women the rate is 33% (Van
Voorhis and Syrop, 2000). In Finland, the total number of treatments initiated increases by
approximately one thousand per year.  In 1997, 19 Finnish centres provided 7336 IVF/ICSI and frozen
embryo transfer (FET) treatment cycles, so that 2.4% of all newborns were the results of ART (Gissler
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and Tiitinen, 1999).  Nowadays summary data on clinical outcomes after ART are collected nationally,
internationally from Europe (European, 2001) and from the USA (ASRM, 2000) and also from the
World (Tarlatzis and Bili, 2000). The pregnancy and delivery rates can be given per initiated cycle, but
usually the results per oocyte retrieval /OPU or per ET are favoured.
Table 5.  Assisted reproduction techniques (ART) with delivery rates / embryo transfer (ET) in 1997  in
the USA, in Europe and in Finland.
                                                                                                                                                                
Delivery rate / ET1  %
ART method                                                                                                                          USA2  Europe3 Finland4        
IUI Intrauterine insemination 5-15
Transfer of prepared (washed) spermatozoa into uterine cavity
IVF-ET In vitro fertilization and embryo transfer 30 21 21
Aspiration of oocytes, fertilization and follow-up of cleavage in culture,
transcervical transfer of embryos into the uterine cavity at the 2- to 8-cell
stage or at the blastocyst stage
ICSI Intracytoplasmic sperm injection 29 22 22
Fertilization of oocytes by injecting one sperm into the nucleus of an
oocyte and transcervical transfer of the embryo
Special techniques for obtaining sperm:
TESE Testicular sperm extraction
MESA Microsurgical epididymal sperm aspiration
GIFT Gamete intrafallopian tube transfer 30 - -
Sperms and oocytes are inserted into the fallopian tube under laparoscopy
ZIFT Zygote intrafallopian transfer 30 - -
Fertilized oocytes are inserted into the fallopian tubes under laparoscopy
FET Transcervical transfer of frozen-and-thawed embryos 19 12 13
Other techniques
Cryopreservation
Freezing of sperm, oocytes or embryos for further use
Assisted hatching
Drilling of zona pellucida to improve embryonic development
Prolonged culture of embryos
Follow-up of embryos to the 8-cell or the blastocyst stage before ET
Blastomere biopsy
From a 6- or 8-cell embryo, one or two blastomeres are taken for
            prenatal diagnosis of a hereditary disease                                                                                      
1
 mean number of embryos replaced (% multiple births): the USA 4 (39%); Europe 53%  • 3 (29%); Finland 1.7 (22%)
2 Data of 73 069 cycles, Society for Assisted Reproductive Technology (SART) Clinical Outcome Reporting System, reported by SART
and American Society for Reproductive Medicine (ASRM, 2000)
3 Data of 203 893 cycles, European IVF Monitoring Programme, reported by European Society for Human Reproduction and Embryology
(European, 2001)
4 Data of 7336 cycles, Finnish IVF Registry, reported by National Research and Development Center for Welfare and Health (Gissler and
Tiitinen, 1999)
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Figure 4.  A model for ovarian hyperstimulation with long pituitary downregulation 
with the GnRH agonist.
 
FSH: follicle-stimulating hormone; GnRH: gonadotrophin-releasing hormone; 
hCG: human chorionic gonadotrophin; hMG: human menopausal gonadotrophin;  
OPU: ovum pick-up / ovum retrieval; TVS: transvaginal ultrasound
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2.2.1. Controlled ovarian hyperstimulation
Because the pregnancy rate obtained with IVF in normal cycles is low (12%), a part of 
ART is hyperstimulation of the ovaries with gonadotrophins (Daya et al ., 1995).  The 
controlled hyperstimulation programme usually includes pituitary down-regulation with a 
GnRH agonist and administration of gonadotrophins (Figure 4). The ovarian response is 
monitored by serial measurements of serum E2 and by measurements of the count and size
of follicles with the aid of transvaginal ultrasound examination and the dosage of 
gonadotrophins is adjusted accordingly. Injection of gonadotrophins for 8 to 10 days 
usually results in the development of 3 to 15 follicles in both ovaries. When at least three 
follicles, each exceeding 16 mm in diameter, have developed, hCG (5 000-10 000 IU) is 
injected subcutaneously, and the oocyte pick-up (OPU) is performed transvaginally 34-36 
hours later.  To ensure endometrial receptivity, progesterone is administered continuously 
after ET. 
Ovarian hyperstimulation causes a 4-fold increase in serum FSH, a 20-fold increase in E2,
a 1.4-fold increase in androstenedione and a 2.6-fold increase in testosterone 
concentrations from suppressed levels (Bützow et al ., 1999; Fanchin et al ., 2000).  After 
ovarian hyperstimulation, the level of E2 in the blood is 4- to 10-fold higher (Fishel and 
Jackson, 1989) and that of progesterone as much as 10-fold higher than during a normal 
menstrual cycle (Fanchin et al ., 2000).  
21
2.2.2 In vitro fertilization
In vitro fertilization (IVF) was originally developed for treatment of infertility that was caused by tubal
occlusion (Edwards et al., 1969). The first IVF baby in the world was born in 1976 in England (Steptoe
and  Edwards, 1978) and the first one in Finland in 1984 (Koskimies et al., 1984). Since then, this
technique has spread to treatment of almost all types of infertility. In 1992-97, for example, 28% of
Finnish couples treated with IVF had tubal infertility, 19% some other female infertility, 15% male
infertility, 14% combined causes, and 18% unexplained infertility (Gissler and  Tiitinen, 1999).  IVF is
most successful if several oocytes are retrieved with the aid of controlled ovarian stimulation.  The
retrieved oocytes are then fertilized with specifically prepared semen and the 4- to 8-cell-stage
embryo(s) are transferred transcervically into the uterus on the 2nd or 3rd day after OPU (Steptoe and
Edwards, 1978). For luteal support, natural progesterone is administered daily either intravaginally or
intramuscularly after ET. Before the introduction of natural progesterone for clinical use, luteal support
was achieved by giving hCG injections (at repeated dosages of 1500-10 000 IU), which stimulated the
production of endogenous progesterone (Barbieri, 1999a).
The pregnancy rate with IVF varies from clinic to clinic, and is dependent on the experience of
the IVF clinic, on the age of the female, and on the number and quality of embryos replaced.  In 1997
the mean pregnancy rate per ET was 37% in the USA (ASRM, 2000), ranged from 18 to 45% in
Europe and was 27% in Finland (European, 2001) (Table 5) and is known to be the same for at least the
first three attempts (Croucher et al., 1998). The pregnancy rates are comparable to normal fecundability
(25-30%) in one cycle. However, early pregnancy failure with ART is common (20%), and some of the
pregnancies are ectopic (2-4%), so the live birth rate varies from 20 to 30% (Gissler and  Tiitinen,
1999; ASRM, 2000) (Table 5). If there are surplus embryos, they are cryopreserved and can be thawed
in future natural cycles or in cycles induced with oestrogen and progesterone with or without pituitary
suppression with a GnRH analogue.  The pregnancy rates with FET are somewhat lower than with
transfer of fresh embryos, and the multiple pregnancy rate is also lower (Table 5). Thus, one IVF
treatment may allow several attempts to induce pregnancy.
2.2.3. Intracytoplasmic sperm injection
The technique of injecting a single sperm under the microscope directly into the cytoplasm of the
oocyte is called ICSI (Palermo et al., 1992). This method has meant a revolution in the treatment of
male infertility, because, almost always, a single sperm can be retrieved, if not from ejaculated semen,
then from the testis or epididymis. In addition, ICSI is indicated for couples with fertilization problems
in IVF treatment.  Fertilization and pregnancy rates are comparable with those in standard IVF
procedures (Tarlatzis and  Bili, 2000) (Table 5).  The ovarian hyperstimulation programme for ICSI is
similar to that of conventional IVF.  However, some concern has arisen over ICSI, because severe male
infertility may be caused by chromosomal aberrations (2% of cases of male infertility) and, if ICSI is
used, these aberrations may be carried to male offspring.  This may be the only specific risk of ICSI,
because in all other respects infants born after ICSI are comparable with other children (Tarlatzis and
Bili, 2000).
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2.2.4. Donated gametes, donated embryos and surrogacy
Nowadays sperm, oocytes and embryos can all be donated. Donations can be made anonymously, but
donors must be healthy and free of any sexually transmitted disease such as human immune deficiency
virus, or hepatitis B or C.  Because of reduced oocyte quality and an increased risk of aneuploidy with
advancing maternal age, the age of female donors is usually restricted to 35 years.  Donation of sperm
has a long history, because sperm can easily be obtained by masturbation and the properly prepared
sperm can be frozen for later use in intrauterine inseminations or in IVF/ICSI programmes (Lashen et
al., 1999). Cryopreservation of the oocytes still has problems and is very rarely used (Kazem et al.,
1995; Goud et al., 2000). Thus, donation of oocytes requires the use of IVF/ICSI programmes: the
volunteer undergoes an ovarian hyperstimulation programme and OPU, the oocytes are inseminated
with the sperm of the infertile male, and the recipient infertile female receives the embryo(s) in a cycle
primed to the volunteer donor's cycle (Söderström-Anttila and Hovatta, 1995).  Donated embryos are
usually obtained from couples who have undergone successful IVF or ICSI programmes and do not
have any need for their frozen embryos (Lindheim and Sauer, 1999; Van Voorhis et al., 1999;
Kingsberg et al., 2000). In surrogacy, the embryo(s) of the infertile couple derived by IVF/ICSI are
transferred into the uterus of a volunteer female (Goldfarb et al., 2000), and, after delivery, the new-
born is adopted by the infertile couple.
These treatments with donated gametes, embryos or surrogacy are options for infertile couples
who are unable to produce gametes of their own, who have severe genetic aberrations, or who have
such severe anatomical abnormalities that they cannot have children of their own by other treatments.
Thus, the most common indication for donated sperm is azoospermia; for ovum donation, ovarian
insufficiency (Lutjen et al., 1984); and for surrogacy, absence or abnormality of the uterus (Raziel et
al., 2000). With donated sperm, the rates of pregnancy and pregnancy outcomes are good (Lashen et
al., 1999). With ovum donation programme, the pregnancy rate per ET is high (46%), but miscarriages
are frequent (Foudila et al., 1999). The ongoing pregnancies are associated with an increased risk of
first trimester bleeding (53%), pregnancy-induced hypertension (31%), and a high rate of caesarean
delivery (57%) (Söderström-Anttila et al., 1998; Foudila et al., 1999).  Live birth rates with surrogacy
are similar to conventional IVF (Goldfarb et al., 2000; Serafini, 2001).
The use of donated gametes, embryos and surrogacy has aroused much public concern, and
many ethical experts regard them as inappropriate. Thus, in many countries these policies are forbidden
by law (Fasouliotis and Schenker, 2000).  In Finland, no legislation exists so far and both surrogacy
and oocyte donation programmes have been practised (Söderström-Anttila and  Hovatta, 1995;
Hovatta, 2000).
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3. ADVERSE EFFECTS OF INFERTILITY TREATMENT
Several adverse effects due to the use of ovulation inducers are to be expected and are caused
by either hypo- or hyperoestrogenism, which are essential parts of the different treatment regimens
(Derman and Adashi, 1994; Schenker and Ezra, 1994) (Table 6). The most severe complication of
induction of ovulation is OHSS, which develops in 1-10% of patients, the severe forms of which may
be associated with thromboembolism (Whelan and Vlahos, 2000). Adverse effects resulting from OPU
or ET are rare (< 1 %) (Schenker and  Ezra, 1994). However, superovulation and transfer of two or
more embryos in IVF/ICSI cycles carries the risk of a multiple pregnancy and its risks (see below)
(Schenker and  Ezra, 1994; Jacobs and Agrawal, 1998).  In singleton pregnancies after IVF, the rate of
babies small for gestational age is doubled compared to babies born after normal conceptions
(Koudstaal et al., 2000). Children born after IVF/ICSI have not been shown to have increased risk of
malformations (Tarlatzis and Grimbizis, 1999; Tarlatzis and  Bili, 2000) or cancer (Lerner-Geva et al.,
2000).
3.1. Ovarian hyperstimulation syndrome
Both the use of gonadotrophins and / or CC can lead to OHSS (Golan et al., 1989). The major
abnormality in OHSS is increased capillary permeability, resulting in serious fluid-balance aberrations.
The ovarian renin-angiotensin system, the vascular endothelial growth factor (VEGF), histamine,
prostaglandins and various cytokines have been suggested to be responsible for OHSS (Whelan and
Vlahos, 2000). Of these factors, VEGF, which is present in human granulosa cells and follicular fluid,
stimulates angiogenesis, and increases vascular permeability, appears to be one of the most likely
agents in the pathophysiology of OHSS (Levin et al., 1998; Whelan and  Vlahos, 2000).
The risk of OHSS is highest in young (age < 25 years) and lean (BMI <20 kg/m2) patients with
history of allergy, and in patients with PCOS or previous OHSS.  Treatment with a GnRH agonist with
gonadotrophins, with high levels of serum oestradiol (• 7 nmol/L) and with a large number of follicles
(> 15 follicles), and luteal support with hCG leading to pregnancy are also risk factors for OHSS.  The
symptoms occur with increasing serum levels of hCG and thus usually regress within the first week
after hCG injection but are aggravated again if pregnancy ensues.  The clinical findings in OHSS
include cystically enlarged ovaries, which cause abdominal discomfort and pain. The capillaries in the
ovaries and also those in other parts of the body leak protein-rich fluid, causing ascites, pleural effusion
and hypovolaemia. The severity of OHSS is classified according to these clinical signs (Table 7).
Hypovolaemia can be so grave that it leads to oliguria, electrolyte imbalance, respiratory failure,
disseminated coagulopathy and even to death (Whelan and  Vlahos, 2000). The risk of
thromboembolism in OHSS is caused by hypercoagulative changes, but this risk is further increased by
pressure of the enlarged ovaries against the large pelvic veins (Kaaja et al., 1989; Jacobs and  Agrawal,
1998). It is curious that thromboses can develop in both the veins (Loret de Mola et al., 2000) and the
arteries (El Sadek et al., 1998; Ludwig et al., 1999b; Yoshii et al., 1999 ).
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Table 6.  Adverse effects of ovarian stimulation and in vitro fertilization
(Derman and Adashi, 1994; Jacobs and Agrawal, 1998; Barbieri, 1999a; Barbieri, 1999b; Hughes et al., 2000b)
                                                                                                                        
Factor and adverse effect                                                     Frequency (%)
1. Ovulation inducers 
Clomiphene citrate
Vasomotor flushes  10-20
Visual disturbances      1-3
Headache        1
Adnexal tenderness        5
Cyst formation     < 5
Cervical mucus abnormality
        and luteal phase defect       59
Ovarian hyperstimulation syndrome      NA
Multiple pregnancy, twins     <10
 • triplets       <1
Gonadotrophins:
Allergic reactions      NA
Ovarian hyperstimulation syndrome     1-10
Severeform    <1-2
Hypercoagulable state, thromboembolism
Multiple pregnancy        15
Gonadotrophin-releasing agonists:       NA
Hypo-oestrogenism
Sweating, flushes, Sore vagina
Nasal congestion
2. Oocyte pick-up
Vaginal or intra-abdominal bleeding         <1
Infection        <1
Immunological reactions (ovarian antibodies)          NA
3. Transfer of • 2 embryos
Multiple pregnancy:    25-50
Preterm delivery vs singleton 2- 3 fold
                                    Pre-eclampsia vs singleton               5-10 fold        
NA: percentage not availablle, vs: versus
Prevention of OHSS is based on the identification of high-risk patients and individualizing their
treatment regimen.  There is some evidence that a high serum level of VEGF may predict the risk of
OHSS (Geva and  Jaffe, 2000; Chen et al., 2000).  Moreover, interleukins 6 and 8 (Chen et al., 2000),
inhibin A and B (Enskog et al., 2000) or CA 125 (Scarpellini and Scarpellini, 1992; Ozaksit et al.,
1993) can also be helpful in assessing the risk of OHSS. In patients judged to be at increased risk of
OHSS, the dosage of ovulation inducers has to be kept at the lowest possible and the ovarian response
has to be monitored even more carefully than usual.  In addition, if signs of OHSS are present, it is
wise to forego ET and instead to cryopreserve embryos for further use (Tiitinen et al., 1995).  It is
possible that in the future the risk of OHSS can be further reduced by using GnRH antagonists instead
of GnRH agonists, or totally abolished by the use of in vitro maturation of oocytes (Suikkari et al.,
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2000).  If, however, severe OHSS ensues, anti-angiogenetic agents, such as VEGF antagonists
or VEGF synthesis inhibitors, may provide effective treatments in future (Whelan and  Vlahos, 2000).
Regardless of the modalities for prevention and treatment of OHSS, the recovery of the ovaries after
severe OHSS has to be followed carefully, because OHSS may indicate an increased risk of ovarian
malignancy (Atlas and Menczer, 1982).
3. 2. Multiple pregnancy
The rate of spontaneous twins is about 1% of all pregnancies and that of triplets 0.01-0.02%.  With the
use of CC, the overall rate of twinning increases to 6-10% and with the use of gonadotrophins for
induction of ovulation it rises to 10-40%, depending on the quality of monitoring the treatment.  Of
interest is, that with the use of ovulation inducers monozygotic twinning seems to be increased 3-fold.
With ART in Europe, the overall rate of multiple births is still high (Table 5; twins 26%, triplets 4%,
quadruplets 0.2%) (European, 2001) and in Finland it is 27% for IVF, 23% for ICSI, and 17% for FET
(Gissler and  Tiitinen, 1999).
Multiple pregnancy is associated with medical, financial, psychological and social risks (Elster,
2000), especially with an increased risk of maternal complications and fetal loss caused by prematurity.
Low birthweights (<2500g) are common (24%) among children born after IVF or ICSI treatment; most
of them are being due to multiple pregnancies.  With triplets or higher-order multiples, multifetal
pregnancy reduction (induced abortion) has been performed to improve the outcome for mother and
children (Elster, 2000).  This procedure, which raises ethical concerns and carries an increased risk of
losing the pregnancy, is more common in countries where transfer of multiple embryos is common.  In
Scandinavia, a general consensus exists that the best way to reduce multiple pregnancies with ART is
single embryo transfer, which can give clinically comparable results (pregnancy rate / ET from 20 to
39% (Vilska et al., 1999; Strandell et al., 2000).
Table 7.  Classification of ovarian hyperstimulation syndrome (OHSS) and need for
hospitalization (Golan et al., 1989; Whelan and Vlahos, 2000)
                                                                                                                                                                        
Symptom Classification of OHSS                                                                                                        
or finding       Mild / Grade 1-2                   Moderate / Grade 3               Severe / Grade 4-5                
Abdominal Distension/discomfort, Grade 1-2 Grade 3 
Nausea, vomiting, +Ascites by ultrasound +Clinical evidence of ascites
and/or diarrhoea
Ovarian Size 5-12  cm
Respiratory - Hydrothorax, tachypnea
Haematology - Mild haemoconcentration Severe haemoconcentration
Coagulation abnormalities
Renal                                                                                                              Diminished renal perfusion
Hospitalization Not required                       Individual judgement           Necessary                              
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4.  INFERTILITY, INFERTILITY TREATMENTS, AND RISK OF GYNAECOLOGICAL
     MALIGNANCIES
The most common cancer in women is breast cancer, accounting for approximately 30% of all cancers,
whereas genital cancers account for 15%.  Accordingly, in 1997 3324 women in Finland were
diagnosed as having breast cancer, 663 women had endometrial cancer, 620 women had ovarian or
fallopian tube cancer or borderline tumours, 160 women had cancer of the uterine cervix, and 106
women had cancers of other genital origin (Finnish Cancer Registry, 1997). Malignancies originating
from the breast, the endometrium or the ovary may, to some extent, have endocrine aetiology,
oestrogen appearing to have the most conspicuous impact (Henderson et al., 1993) (Table 8).
Furthermore, nulliparity and advanced age at the first delivery are common risk factors for these three
cancers (Kvale et al., 1991).  Therefore it is no wonder that infertility itself is a risk factor for these
cancers, especially in view of the fact that infertility is often linked with elevated levels of oestrogens
and/or gonadotrophins (Brinton et al., 1989; Anttila et al., 1994).  This brings us to ovulation inducers,
which can induce multiple follicles and stimulate release of gonadotrophins and/or oestrogen (Balen,
1995; Meirow and Schenker, 1996; Rodriguez et al., 1998a).  Gonadotrophin receptors are expressed
on all the cells of ovarian inclusion cysts but in only 50-60% of cells of ovarian cancers; this may
suggest a role for gonadotrophin in ovarian cancer biology (Ala-Fossi et al., 1999; Konishi et al.,
1999). The roles of FSH and LH may be different in this respect, because LH has been shown to block
the cell-proliferating effect of FSH on ovarian cancer cell lines (Zheng et al., 2000).
The report of a 27-fold risk of ovarian cancer after infertility treatment (Whittemore et al.,
1992) together with numerous case reports of infertile patients with gynaecological cancers (Bandera et
al., 1995; Tarlatzis et al., 1995; Unkila-Kallio et al., 1997) have demonstrated a need for further studies
on the risk of genital malignancies in infertile patients, and such data are now available from Australia,
Denmark, Israel, Italy and the USA, (Rossing et al., 1994; Venn et al., 1995; Bristow and Karlan,
1996; Rossing et al., 1996a; Parazzini et al., 1997; Garland et al., 1998; Modan et al., 1998; Rodriguez
et al., 1998a; Weiss et al., 1998; Venn et al., 1999) (Tables 10a and 10b). Radiotherapy treatment for
infertility has not been associated with increased risk of gynaecologic malignancies (Ron et al., 1999).
4.1. Ovarian malignancies
The incidences of ovarian malignancies in the USA and Northern Europe are the highest in the world,
being 10.9/100 000 in Finland or 14.7/100 000 when borderline tumours and tubal cancers are also
included (Finnish Cancer Registry, 1997). The risk of developing ovarian cancer before the age of 65 is
0.8%. This risk is reduced to 0.3% if the woman is multiparous or if she has used oral contraceptives
(OC) for at least 4 years, but increased to 1.6% if she is nulliparous and has not used OC. Belonging to
a family with hereditary cancer syndrome increases the life-time risk to 4.4%.(Hartge et al., 1994).
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Table 8.  Theories of the causes of ovarian cancer (+ = supports, ? = questions the theory)
                                                                                                                                                                
Theory                                                                                                                                                                                   
Incessant ovulation:
Extravagant, purposeless ovulations cause ovarian trauma and the repair of the trauma induce genetic
alterations within the surface epithelium (Fathalla, 1971) or formation of epithelial inclusion cysts and
development of neoplastic cells (Resta 1993; Tressera et al., 1998; Ness and Cottreau, 1999).
Inflammation:
Cell damage (ovulation) induces secretion of potentially mutagenic cytokines and prostaglandins that may
participate in malignant transformation (Ness and Cottreau, 1999; Doraiswamy et al., 2000)
+ Longer ovulatory age is associated with ovarian cancer (Casagrande et al., 1979; Schildkraut et al.,
    1997; Webb et al., 1998)
+ Pregnancies and oral contraceptives decrease the risk of ovarian cancer (Hankinson et al., 1992;
Adami et al., 1994; Hankinson et al., 1995 )
+ Endometriosis is associated with ovarian cancer (Brinton et al., 1997)
? Anovulatory infertile patients run an increased risk of ovarian cancer (Schildkraut et al., 1996)
? Oral contraceptives or parity do not reduce the risk of mucinous ovarian cancers (Risch et  al., 1996)
Gonadotrophins: 
Gonadotrophins may have direct carcinogenic activity (Cramer and Welch, 1983): gonadotrophins stimulate cell
growth and inhibit apoptosis in ovarian epithelial cells and ovarian cancer cells (Konishi et al., 1999) and
promote the growth of ovarian cancer by inducing angiogenesis (Schiffenbauer et al., 1997).
Oestrogens:
Oestrogens increase granulosa cell proliferation and hence the frequency of mitotic activity, which may lead to
malignant transformation (Cramer and Welch, 1983)
+ Gonadotrophin and oestrogen receptors are expressed in ovarian tumours (Konishi et al., 1999)
+ The incidences of gynaecological malignancies increases after the menopause (Stadel, 1975)
+ In rodents, high levels of gonadotrophins induce GCT (Biskind et al., 1952; Tennent et al., 1990)
+ Excess of oestrogens and androgens may increase the risk of ovarian cancer, whereas progesterones
   may be protective (Risch, 1998, Rodriguez et al., 1998b)
+ The use of non-contraceptive oestrogens / hyperoestrogenism increase the risk of ovarian
   endometrioid cancer (Risch et al., 1996; Zanetta et al., 2000)
+ Prolonged use (• 10 years) of oestrogen replacement therapy associates with increased risk of
   ovarian cancer mortality (Rodriguez et al., 2001)
+ GnRh analogues show promise for therapy of ovarian cancers (Schally 1999b)
? Oestrogen replacement therapy was not associated with ovarian cancer in a meta-analysis (Coughlin
    et al., 2000)
Infection:
Pelvic inflammatory disease may induce secretion of potentially mutagenic cytokines and prostaglandins that
may induce malignant transformation (Ness and Cottreau, 1999)
+ Tubal ligation and hysterectomy reduce the risk of ovarian cancer (Hankinson et.al., 1993)
+/? The association of pelvic inflammatory disease with ovarian cancer is inconsistent (Risch and Howe,
1995; Parazzini et al., 1996)
Genetic inheritance:
Approximately 3-13% of ovarian cancers are familial, either site-specific ovarian cancers, hereditary breast
ovarian cancers, or hereditary nonpolyposis colon cancers / ovarian cancer syndrome / Lynch syndrome II
                (DePasquale et al., 1998)                                                                                                                                                                   .
GCT: granulosa cell tumours
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Ovarian malignancies in Danish women between 18 and 59 years of age originated from germ
cells (3-4%), sex-cord stromal cells (3-4%) or ovarian epithelial cells (80-90%) or were unclassifiable
or metastases (6%) (Mosgaard et al., 1997b).  Of these malignancies, those of stromal origin, especially
GCTs, and epithelial cancers are thought probably to be associated with infertility treatments (Tarlatzis
et al., 1995).
4.1.1. Granulosa cell tumour
Granulosa cell tumour (GCT, Figure 5) is the most common of the sex-cord stromal tumours of the
ovary and it is often capable of producing steroids, especially oestrogen (Table 9) (Serov et al., 1973;
Young and Scully, 1994).  Approximately 2-3% of all ovarian tumours are GCTs (Young and  Scully,
1994; Platz and Benda, 1995). Their incidence ranges from 0.58 / 100,000 in Israel to 1.6 / 100,000 in
Sweden (Stenwig et al., 1979; Björkholm and Silfversward, 1980; Ohel et al., 1983).
Granulosa cell tumours can be divided into juvenile and adult types, which are both typically of
low malignant potential, but have a tendency to recur even 30 years after primary treatment (Hines et
al., 1996). All GCTs should therefore be classified and followed up like ovarian malignancies (Fox et
al., 1975). Juvenile GCTs account for 5% of all GCTs and are usually associated with precocious
puberty (Cronje et al., 1998). The more common adult type of GCT is typically diagnosed in
postmenopausal women complaining of bleeding, an abdominal mass or haemoperitoneum. The
symptoms of GCT are mostly related to hyperoestrogenaemia (pubertas praecox, menorrhagia, or
postmenopausal bleeding with endometrial hyperplasia or cancer) (Ohel et al., 1983) or to high levels
of inhibin (secondary amenorrhea) (Lappohn et al., 1992). The histology of a GCT is complex, and
often specific stainings are needed for a final diagnosis (Gitsch et al., 1991; Choi et al., 2000).
Assessment of inhibin, (Kauppila et al., 1992; Burger et al., 2000; Ala-Fossi et al., 2000) and/or
Müllerian inhibiting substance (Lane et al., 1999) in the serum can be of help in the follow-up of
patients with GCT.
In rodents, GCT development can be induced by high levels of gonadotrophins (Biskind et al.,
1952), especially if inhibin production is prevented (Matzuk et al., 1996; Beamer et al., 1998;
Rilianawati et al., 1999).  The association of high gonadotrophins and GCT has led to a search for
activating mutations of the FSH receptor in these tumours, but so far none has been found (Fuller et al.,
1998). Recently, oestrogen β-receptor was detected in GCT, implying that oestrogen may have a role in
the pathogenesis of GCT (Chu et al., 2000).  In addition, chromosomal aberrations (trisomy 12,
genomic imprinting) may be causative factors, at least in juvenile GCT (Fletcher et al., 1991; Beamer
et al., 1998).  Because ovulation inducers increase gonadotrophin levels, it has been suggested, on the
bases of case reports in infertile women, that the use of ovulation inducers may cause an increase in
GCTs in infertile women (Willemsen et al., 1993). Of the other sex-cord stromal tumours, Sertoli-
Leydig cell tumour in an infertile patient has been reported (Chou et al., 1997).  On the other hand, it
has been shown that each pregnancy reduces the risk of GCT by 16% (Adami et al., 1994).
Unfortunately, most of the epidemiological studies on ovarian malignancies lack specific data on GCTs
and studies on GCT do not include the data on infertility treatments.
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4.1.2. Epithelial cancers
More than 90% of ovarian cancers arise from a single epithelial cell (Bast et al., 1995), preferably in
ovarian inclusion cysts (Tresserra et al., 1998). It is commonly believed that the onset of cancer of this
type is preceded by premalignant stages, such as an epithelial tumour of low malignant potential, a
borderline ovarian tumour (Scully, 2000), or an endometriotic cyst (Vercellini et al., 2000), and further,
because morphological precursors of ovarian epithelial cancer are evident (Resta et al., 1993) and the
risk factors for these tumours are similar to those for invasive ovarian cancer (Harlow et al., 1988;
Eltabbakh et al., 1999). Interestingly, the borderline tumours seem more frequently to be associated
with infertility (Mosgaard et al., 1998; Duska et al., 1999), or its treatments (Harris et al., 1992;
Parazzini et al., 1998) than the invasive cancers (Tables 10a and 10b).  The epithelial cancers are
classified as serous type (80-90%),  mucinous, endometrioid, clear cell, and Brenner tumours.
Cigarette smoking, the classical risk factor for many cancers, is a risk factor only for mucinous
epithelial ovarian cancer (odds ratio, OR 2.9, 95% confidence interval, CI95% 1.7,4.9) (Marchbanks et
al., 2000).
From epidemiological studies on ovarian cancer it is known that the risk of ovarian cancer decreases
with long-term use of combined types of OC or GnRH agonists (Henderson et al., 1993), whereas low
parity, infertility (Rodriguez et al., 1998a) and infertility treatments probably increase the risk
(Whittemore et al., 1992). This study by Whittemore had used combined data from small-scale USA
case-control studies and its finding of a 27-fold risk in treated nulliparous infertile women received
much criticism, as the study lacked data on the causes of infertility, or the treatment received and
suffered from the small number of cases.  In subsequent epidemiological study on infertile patients, the
use of CC for 12 months or more was associated with an increased risk of ovarian cancer in both
anovulatory and ovulatory infertility (relative risk [RR] 11.1, CI95% 1.5-82.3) (Rossing et al., 1994), but
studies thereafter have not supported this relationship (Mosgaard et al., 1997b) (Tables 10a and 10b).
In a Danish study of 684 women with ovarian cancer (all types), only 4.1% had undergone hormonal
ovarian stimulation (Mosgaard et al., 1997b), i.e., not more frequently than the control subjects.  The
Danish authors, like the others, concluded that the risk factors for ovarian cancer were infertility and
nulliparity, not the treatment of infertility (Mosgaard et al., 1997b).  The largest study so far has
included 29,700 women referred for IVF treatment in Australia (Venn et al., 1999).  This study showed
an increased risk of ovarian cancer in patients with unexplained infertility (Table 10b).  In addition to
unexplained infertility, anovulatory infertility has also been related to an increased risk of ovarian
cancer (OR 2.5, CI95% 1.1-5.9) (Rossing et al., 1994), especially if body mass index (BMI) was low in
patients with PCOS (Schildkraut et al., 1996).  Patients with endometriosis have been found to have an
increased risk of ovarian cancer (standardized incidence ratio [SIR] 1.9, CI95% 1.3-2.8) regardless of
fertility, the risk has been highest with ovarian endometriosis (SIR 4.2, CI95% 2.0-7.79) (Brinton et al.,
1997) and the increased risk has also been associated with the use of non-contraceptive oestrogens
(Risch et al., 1996).  Further, patients who carry a hereditary or sporadic mutation linked to ovarian
cancer may run a higher risk of ovarian cancer when they undergo ovarian hyperstimulation (Nieto et
al., 1999).
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4.2  Endometrial cancer
In Finland in 1997, the incidence of endometrial cancer was 14.3 / 100,000 (Finnish Cancer Registry,
1997).  Long-term exposure to oestrogen action alone increases the risk of endometrial cancer
(Henderson et al., 1993; Beral et al., 1999) as does also tamoxifen (Cardosi and Fiorici, 2000). In
addition, patients with a hereditary tendency to nonpolypotic colorectal cancer or endometrial cancer
are at increased risk of developing endometrial cancer (Hakala et al., 1991; Lynch et al., 1998).  Tubal
sterilization has no effect on this risk (Lacey et al., 2000).   Endometrial cancer at age • 45 year of age
has been related to obesity (• 90 kg, OR 5.5, CI95% 2.9-10.6), infertility (OR 3.6, CI95% 1.3-9.9), family
history of colonic carcinoma (OR 5.0, CI95% 1.3-19.1) and nulliparity (OR 2.8, CI95% 1.1-7.2) (Farquhar
et al., 1999). Epidemiological studies in infertile patients raise especially those with progesterone
deficiency (SIR 9.4, CI95% 5.0-16.0) and patients with PCOS or obesity (Modan et al., 1998; Klip et al.,
2000) with increased risk which is independent of infertility treatment (Modan et al., 1998).  In
addition, unexplained infertility appears to be a risk factor, although its impact is not so strong (SIR 4.6
,CI95% 1.9-11.0) and was reduced in IVF-treated patients (Venn et al., 1999). However, within 12
months after IVF the risk of endometrial cancer after IVF may be increased (Venn et al., 1999).
4. 3. Cervical cancer
In Finland, the incidence of cervical cancer, which was 3.9 / 100,000 in 1997 has been decreasing until
the last few years, when it has started to increase again. Among women with a history of infertility, the
risk of cervical cancer is low (SIR 0.5, CI95% 0.4-0.7), although tubal occlusion may predispose to this
risk (Rossing et al., 1996a). This finding is supported by a recent association between Chlamydia
trachomatis infections and cervical cancer (Koskela et al., 2000).  As regards infertility treatments, it is
known that patients treated with CC have a reduced risk of cervical cancer (RR 0.4, 95% CI95% 0.2-0.8)
(Rossing et al., 1996a).
4.4. Breast cancer
The incidence of breast cancer in Finnish females was 78.6 /100,000 in 1997 (Finnish Cancer Registry,
1997).  Advanced age at the first pregnancy (Apter, 1996), nulliparity, infertility (Weiss et al., 1998),
and obesity are well-established risk factors for breast cancer. In addition, endometriosis, regardless of
infertility, appears to be an independent risk factor for breast cancer (SIR 1.3, CI95% 1.1-1.4) (Brinton et
al., 1997).  In contrast, young age at the first full-term pregnancy, multiparity, leanness and physical
activity appear to protect against breast cancer (Hoffman-Goetz et al., 1998).
The stimulatory effect of E2 on neoplastic mammary cells in vitro is well established (Fuqua et al.,
2000), but the roles of gonadotrophins and progesterone are less clear (Bernstein et al., 1995;
Thompson and Ambrosone, 2000).  Earlier studies on infertile women have suggested an increased risk
of breast cancer in patients with progesterone deficiency, but later studies did not confirm this
association. Epidemiological data have so far failed to show any association between infertility
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treatments and breast cancer (Rossing et al., 1996b; Westhoff, 1996; Ricci et al., 1999).  Furthermore,
the prospective Nurses´ Health Study II on 116,678 women between 25 and 42 years of age showed a
reduced risk of breast cancer in women with ovulatory infertility (RR 0.41, CI95% 0.2-0.9) (Garland et
al., 1998).  According to one study, however, it may be that within 12 months after IVF the risk of
breast cancer is slightly increased (SIR 2.0, CI95% 1.2-3.2) (Venn et al., 1999). Infertile patients carrying
breast cancer gene 1 or 2 mutations (BRCA1, BRCA2) may form a special subgroup, because
pregnancy in these patients increases, rather  than decreases,  the risk of breast cancer (Jernstrom et al.,
1999).  Thus these patients need counselling and perhaps a more conservative approach towards
infertility treatments (Armstrong et al., 2000).
5.  BIOREGULATORS SECRETED BY GRANULOSA CELLS
Granulosa cells surrounding the developing oocyte are separated from the stroma by a basement
membrane (Figure 2).  Because the granulosa cell layer is avascular, the regulation of granulosa cell
function occurs mainly through paracrine or autocrine mechanisms (Geva and  Jaffe, 2000). During
follicular development, the number of granulosa cells increases 160-fold, there being approximately 47
million such cells in a mature follicle (Gougeon, 1986).  In addition to E2, granulosa cells secrete
several bioregulators which operate locally in a paracrine and autocrine fashion (Table 3).  Yet it must
be acknowledged that, although these bioregulators function in vitro, we have not enough evidence to
be sure that they function in vivo (Yeh and  Adashi, 1999).  During luteinization, granulosa cells
undergo rapid neovascularization to form the corpus luteum (Geva and  Jaffe, 2000).  The corpus
luteum begins to secrete progesterone and other substances that are essential for endometrial
maturation, implantation and the maintenance of early pregnancy. If pregnancy does not occur, no hCG
is available and the corpus luteum becomes avascular and non-functional within 14 days.  The
regulation and function of the human corpus luteum is still not fully understood, but paracrine and
autocrine bioregulators may be significant (Reynolds and Redmer, 1999).
5.1. Inhibins and activins
Inhibins consist of an α-subunit linked to either a βA-subunit to form inhibin A (αβA) or to a βB-subunit
to form inhibin B (αβB) (McLachlan et al., 1987).  Inhibins selectively suppress the synthesis and
secretion of FSH from the pituitary, whereas activins, which are homodimers of inhibin β-subunits
(βAβA, or βBβB), stimulate FSH secretion.  During a normal menstrual cycle (Ala-Fossi et al., 1998) and
during ovarian stimulation the level of inhibin B in the serum increases in relation to the E2 level and
follicular development whereas the level of inhibin A is elevated during the luteal phase (Hall and
Welt, 2000).  In patients with GCT and in patients with mucinous ovarian cystadenocarcinomas, the
levels of inhibins are elevated and thus the level of inhibin can serve as a tumour marker in the
diagnosis and follow-up of these patients (Burger et al., 2000).
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5.2. Vascular endothelial growth factor
Vascular endothelial growth factor stimulates angiogenesis and enhances vascular permeability
(Ferrara et al., 1992).  It exists in several isoforms; the most abundant form present in most tissues is
VEGF165 (Geva and  Jaffe, 2000).  From animal studies we know, that VEGF is essential for
angiogenesis of the corpus luteum and further, for progesterone production and endometrial maturation
(Ferrara et al., 1998; Fraser et al., 2000).  Of the female reproductive organs, VEGF has been detected
in follicular fluid (Lee et al., 1997), granulosa cells (Yan et al., 1993; Laitinen et al., 1997), theca cells
(Kamat et al., 1995; Suzuki et al., 1998), endometrial cells (Charnock-Jones et al., 1993; Shifren et al.,
1996), and placental cells (Sharkey et al., 1993; Vuorela et al., 1997).  The synthesis of VEGF is
stimulated, at least in vitro, by gonadotrophins and oestrogen (Shifren et al., 1996; Laitinen et al.,
1997; Huang et al., 1998; Neulen et al., 1998), and by hypoxia (Geva and  Jaffe, 2000).  These
phenomena may also occur in vivo, because patients with PCOS (Agrawal et al., 1998) and patients
with OHSS (Rizk et al., 1997) exhibit high serum levels of VEGF.  It has been suggested that high
VEGF concentrations in the serum on the day of hCG administration (Geva et al., 1999) predict the
risk of OHSS (Artini et al., 1998; Ludwig et al., 1999a) but the data are not consistent (Chen et al.,
2000). On the other hand, it is known that the levels of VEGF in the serum correlate to those measured
from follicular fluid (Lee et al., 1997) and in follicular fluid, elevated levels of VEGF at time of oocyte
retrieval have associated with reduced fertility and suboptimal embryo development (Friedman et al.,
1998; Barroso et al., 1999). Studies on VEGF in patients with endometriosis suggest a role for VEGF
as an aetiologic factor in endometriosis (Pellicer et al., 2000).  Thus, the role of VEGF in ART awaits
further confirmation
The data on the circulating levels of VEGF during a normal menstrual cycle are not uniform.
Some authors have reported fairly stable levels (Lee et al., 1997; Yamamoto et al., 1997b; Chung et al.,
1998) whereas others have found a decrease during the luteal phase of the menstrual cycle (Heer et al.,
1998).  In normal cycles a close dynamic relationship exists between serum progesterone and VEGF
concentrations in the follicular fluid (Anasti et al., 1998).  When interpreting these serum data, it has to
be acknowledged that VEGF is also synthesized by platelets (Banks et al., 1998; Wartiovaara et al.,
1998), vascular smooth muscle cells (Tischer et al., 1991) and macrophages (Berse et al., 1992). These
sources are affected by the collection of blood samples and therefore they may well contribute to the
VEGF level in the serum (Banks et al., 1998) and cause erroneous readings in the assay if the blood
sample has not been collected gently.
A role for VEGF as a tumour marker/prognostic factor in breast and ovarian cancers has been
proposed (Yamamoto et al., 1997a; Tempfer et al., 1998; Gasparini, 2000; Shen et al., 2000). The
preoperative serum VEGF concentration has been an independent prognostic factor for ovarian
malignancy when stage, histological grade and lymph node involvement were included in the analysis
(Tempfer et al., 1998), but not if CA 125 was added to multivariate analysis (Obermair et al., 1998).
On the other hand, patients with malignant (especially serous) ovarian cystic tumours had significantly
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higher levels of VEGF both in the follicular fluid and in the serum than patients with benign ovarian
tumours (Boss et al., 2001).  Taken together, the present data suggest that VEGF is an important factor
in physiological and unphysiological angiogenesis in the genital organs (Geva and  Jaffe, 2000) and it
is possible that VEGF has potential to become a tumour marker for ovarian tumours.
5.3. Leptin
Leptin acts as a signal between the hypothalamus and the adipose tissue, which is the main energy
reserve (Zhang et al., 1994; Montague et al., 1997; Himms-Hagen, 1999). In addition, it may have a
permissive role in female puberty (Apter, 1997), because its levels increase at puberty and are two to
three times higher in women than in men (Koistinen et al., 1998).  Administration of leptin to leptin-
deficient, infertile obese mice not only reduced their weight but restored their fertility (Barash et al.,
1996). In a leptin-deficient girl, administration of leptin induced detectable LH pulses, which are
essential for the initiation of menstrual cycles (Farooqi et al., 1999). Thus, leptin seems to be a
regulator in human reproduction. In addition, it is an angiogenetic factor (Bouloumie et al., 1998) and
may have a role in haemopoiesis and immunity (Gonzalez et al., 2000).
Most of the leptin present in human blood is secreted from white fat cells, but in women of fertile
age a minor part may also come from the granulosa cells (Antczak et al., 1997) and during pregnancy
also from the placental cells (Masuzaki et al., 1997). The secretion of leptin is pulsatile and seems to be
synchronized with the LH pulses (Licinio et al., 1998). Leptin receptors are expressed in the anterior
pituitary, in some other parts of the brain, in the ovarian granulosa and theca cells, and in the secretory
endometrial cells (Gonzalez et al., 2000).  During a normal menstrual cycle, the leptin levels in the
serum rise during the follicular phase and reach their peak during the luteal phase (Hardie et al., 1997;
Shimizu et al., 1997; Mannucci et al., 1998; Messinis et al., 1998; Riad-Gabriel et al., 1998; Cella et
al., 2000). However, not all data are in line with this conclusion, since stable levels of leptin have been
reported during the menstrual cycle (Teirmaa et al., 1998; Cella et al., 2000).  The regulation of leptin
secretion in humans is complex (Figure 1), but E2 is thought to have a stimulatory role (Mannucci et
al., 1998; Messinis et al., 1998; Strowitzki et al., 1998; Bützow et al., 1999; Stock et al., 1999;
Lindheim et al., 2000; Zhao et al., 2000).  The production of leptin from trophoblasts (Masuzaki et al.,
1997) contributes to the raised serum levels of leptin during pregnancy (Laivuori et al., 2000).
It is not known whether leptin has a role in human infertility. The data on leptin levels in women
with PCOS, a disease often associated with obesity and anovulatory infertility, are inconsistent
(Brzechffa et al., 1996; Caro, 1997; Rouru et al., 1997; El Orabi et al., 1999; Jacobs and Conway,
1999; Sir-Petermann et al., 1999). In patients with endometriosis, the levels of leptin in the serum and
peritoneal fluid have been found to be higher than (Matarese et al., 2000) or similar to (Matalliotakis et
al., 2000) those in matched control subjects.  Leptin levels were lower in advanced-stage endometriosis
than in early stage endometriosis (Matarese et al., 2000) and treatment with GnRH agonist (leuprolide)
and danazol increased the leptin levels (Matalliotakis et al., 2000).  Leptin receptors are, indeed,
present in endometrial cells (Kitawaki et al., 2000) making it seem probable that leptin has a role, not
only in pathophysiology of the endometriosis, but also in the infertility caused by endometriosis,
probably in unexplained infertility, and also in implantation and thus in predicting the outcome of ART
(Mantzoros et al., 2000).  Recently, subfertile ovulatory patients with the endometrial maturation defect
were shown to be deficient in functioning leptin receptors, in spite of adequate concentrations of serum
hormones and normal steroid hormone receptors (Alfer et al., 2000). However, these data are sparse
and at present no consensus exists with regard to the impact of leptin in human infertility.  In addition,
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the ability of leptin to induce angiogenesis (Bouloumie et al., 1998) and the stimulatory effect of
hypoxia on its secretion (Barroso et al., 1999) may link leptin with tumours, probably at least with
breast cancer (Tessitore et al., 2000).
6. TUMOUR MARKERS ASSOCIATED WITH GENITAL CANCERS
Tumour markers are compounds (usually proteins) produced by malignant cells which appear in serum
in such large quantities that their assessment is possible.  Thus, measurement of these markers may
help the diagnosis and follow-up of these patients (Lindblom and Liljegren, 2000).
6.1. Cancer antigen 125
Cancer antigen 125 (CA 125) is a high-molecular-weight glycoprotein (Bast et al., 1981), the release of
which is linked to the epidermal growth factor (EGF) and cell surface proteases (O'Brien et al., 1998).
The main source of pathological CA 125 production is malignant ovarian cells. Ca 125 is also
expressed in the coelomic epithelium (the mesothelial cells, endometrium, fallopian tubes, endocervix
and amniotic cells) and in the epithelial cells of ovarian cysts and their papillary projections (Zeimet et
al., 1998). Thus elevated levels of CA 125 (• 35 IU/L) can be seen in both benign and malignant
diseases (Table 11) (Halila et al., 1986; Lehtovirta et al., 1990; Bast et al., 1998; Abrao et al., 1999).
However, the levels are much more higher in cancer, especially in the serous type of ovarian cancer,
cancer of the Fallopian tubes and endometrial adenocarcinomas (Bast et al., 1998).
There is no consensus as regards the role of CA 125 in ovarian function. Hyperoestrogenism
may either increase (Lanzone et al., 1990; Zweers et al., 1990; Ozaksit et al., 1993) or cause no change
in the level of CA 125 (Phocas et al., 1994).  Yet patients with OHSS express high levels of serum CA
125 (Jager et al., 1987; Scarpellini and  Scarpellini, 1992; Ozaksit et al., 1993).  In addition, follicle
fluid is rich in CA 125 (Mordel et al., 1992), but ovarian volume is not a determinant of CA 125 in
serum (Granberg et al., 1990).  However, the levels of gonadotrophins or gonadal steroids are not
consistently correlated with serum CA 125 (Lehtovirta et al., 1990; Jimena et al., 1993; Ozaksit et al.,
1993; Bon et al., 1999). The role of CA 125 in predicting the likelihood of pregnancy after IVF-ET is
also disputable (Miller et al., 1996; Brandenberger et al., 1998; Noci et al., 1999; Baalbergen et al.,
2000).  As is evident from the above, healthy reproductive organs produce CA 125 but, in malignancy,
this production is enhanced. Moreover, the impact of ovarian hyperstimulation and/or of IVF on CA
125 levels has not been established so far.
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6.2. Tumour-associated trypsin inhibitor
Tumour-associated trypsin inhibitor (TATI) is a 6 kD peptide isolated from the urine of a patient with
ovarian cancer (Stenman et al., 1982).  Later, TATI was found to be identical to the pancreatic
secretory trypsin inhibitor (Bartelt et al., 1977). One of TATI´s effects is to inhibit the proteolytic
activity of trypsin and other proteases and so prevent the tissue damage that is caused by trypsin release
(Stenman et al., 1991; Marchbank et al., 1998).  In addition, TATI stimulates the growth of human
endothelial cells and stimulates mucosal repair at sites of injury (Marchbank et al., 1998).
In healthy subjects, TATI is present in low concentrations, and removal of the pancreas does
not bring this level to zero (Halila et al., 1985).  Mucus-producing cells in the gastro-intestinal tract,
lungs, liver, kidney, ovary and breast also produce TATI (Marchbank et al., 1998).  In patients with
mucinous ovarian tumours and also in those with some other malignancies serum levels of TATI are
raised (Table 11) (Stenman et al., 1991; Pectasides et al., 1996; Venesmaa et al., 1998).  Moreover, it is
known that endometriosis (Medl et al., 1997) and renal failure (Tramonti et al., 1998) increase the
levels of TATI in serum.  However, TATI levels have not been studied in serum during normal
menstrual cycles nor has its response to ovarian stimulation.
6.3. Free β-subunit of human chorionic gonadotrophin
Human chorionic gonadotrophin is composed of α- and β-subunits.  The β-subunit of hCG (hCGβ) has
84% homology with the LHβ-subunit (Figure 3) and thus both subunits can bind to a common gonadal
receptor (Schally et al., 1999a).  Intact hCG stimulates progesterone production in the corpus luteum
during the first trimester of pregnancy, but the free α- and β-subunits lack gonadotrophic activity
(Albanese et al., 1996).  These subunits are secreted by the pituitary and the placenta, and their
carbohydrate structure depends on their source (Blithe and Iles, 1995). Intact hCG and the β-subunit
are excellent markers for trophoblastic diseases (Alfthan and Stenman, 1996; Vartiainen et al., 1998).
In addition, both subunits are also secreted in a number of non-trophoblastic malignancies (Table 11)
(Braunstein et al., 1978; Iles et al., 1990; Alfthan et al., 1992; Webb et al., 1996).
In non-pregnant women, hCG is secreted in a pulsatile fashion, similarly to LH (Odell and
Griffin, 1987).  In IVF cycles resulting in pregnancy, the level of intact hCG begins to rise 7 to 8 days
after ET and doubles in 1.9 days and peaks 6 to 10 weeks later.  The secretion of hCGβ in relation to
total hCG is highest during the first 2 weeks of pregnancy, then gradually decreasing from the 4th to
the 12th week after the last menstrual period (Alfthan et al., 1988).  The fact that the levels of free
hCGβ may be high in IVF pregnancies may cause false-positive alarms on serum screenings for
Down's syndrome (Wald et al., 1999).  However, the impact of IVF on the two hCG subunits has not
yet been established.
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6.4. Common free α-subunit of glycoprotein hormones
The common free α-subunit of glycoprotein hormones (GPHα) is encoded by a single gene, while β-
subunits of the different glycoproteins are encoded by several different genes (Albanese et al., 1996).
GPHα  is present in serum of both pregnant and non-pregnant women. In non-pregnant women, GPHα
is derived from the pituitary gonadotrophes or thyrotrophes and its secretion is regulated by GnRH and
probably also by oestrogen (Albanese et al., 1996). The biological function of GPHα is not fully
known. It is postulated that it might play a role as a paracrine regulator of prolactin secretion (Blithe
and  Iles, 1995) or human endometrial cell differentiation (Nemansky et al., 1998).
During the menopause the levels of GPHα rise 10-fold, as also during the use of GnRH
agonists, while the use of a GnRH antagonist totally blocks GPHα  secretion (Fluker et al., 1994).
During pregnancy, GPHα  is derived from the placental syncytiotrophoblasts and the levels increase
(Korhonen et al., 1997).  In addition, in patients with malignancies the level of GPHα  may be elevated
(Table 11) (Honegger et al., 1995).  However, the excretion of GPHα during IVF programmes or in
different types of infertility has not been studied.
Table 11.  Some tumour markers used for the diagnosis and follow-up of gynaecological malignancies.
                                                                                                                                                                                                            
Tumour marker         Upper normal limit    Half-life         Causes of elevations in serum (references in text)                         
Cancer antigen 125    35 IU/mL 5-10 days1 Menstruation, I trimester pregnancy,  endometriosis, fibroids,
Adenomyosis, pelvic inflammatory disease, surgery,
Peritonitis, pleuritis, hepatitis, mesotheliomas, immature teratomas
Cancer of the ovary, fallopian tubes, endometrium, breast, colon,
lung, pancreas, and lymphomas.
α-subunit of GPH < 31 pmol/l2 < 6 hours3 Menopause, GnRH analogues, bronchogenic tumours
  Pituitary tumours, carcinoids, insulinomas, cancer of the cervix
β-subunit of hCG   < 1 pmol/L 23 hours3 Pregnancy, trophoblastic diseases,   
Cancer of the ovary, cervix, pancreas, biliary duct, bladder
TATI   < 2 nmol/L 6-8 min4 Smoking, endometriosis, renal failure, mucinous ovarian tumours
                                                                                                Cancer of the ovary, pancreas, lungs, bladder                               
GnRH: gonadotrophin-releasing hormone; GPH: glycoprotein hormone; hCG: human chorionic gonadotrophin; TATI: tumour-associated
trypsin inhibitor.  1Bidart et al., 1999; 2 age < 45 years for age; •45 years upper normal limit < 57.9 pmol/L (Alfthan H, unpublished data);
3Korhonen et al., 1997; 4Marchbank et al., 1998
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III AIMS OF THE STUDY
The present study was undertaken to investigate the impact of the use of ovulation inducers on the
occurrence of GCTs in Finland, and the impact of an IVF programme on agents which are either
derived from ovaries or otherwise associated with gynaecological tumours.
The specific aims were:
1. to study the incidence of GCT in relation to the use of ovulation inducers in Finland in 1965 - 1994,
2. to elucidate the reproductive features of patients with GCT at fertile age,
3. to study the effect of an IVF programme on serum levels of VEGF and leptin,
4. to study the effect of an IVF programme on serum levels of the following tumour markers: CA 125,
    TATI, hCGβ and GPHα,
5. and to study the influence of very early IVF-pregnancy on the serum levels of VEGF, leptin, CA 125
    and TATI.
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IV SUBJECTS AND METHODS
These studies were undertaken during 1995-1999 with the approval of the Ethics Committee of the
Department of Obstetrics and Gynaecology, University Central Hospital, Helsinki. The patients in
studies III-V signed their consent after being informed of the purpose, nature and possible risks of the
study.
1. SUBJECTS
1. 1. Study  I
The study on the incidence of GCT in Finland included all the patients who were diagnosed as having
had GCT and were reported to the Finnish Cancer Registry in 1965-1994 (Table 12). This register
covers almost 100% of the cancer patients in this country (Teppo et al., 1994).  For comparison, all the
patients with ovarian malignancies during the same time period were also studied. Sales statistics of
ovulation inducers (CC, hMG, FSH) and OCs were collected from the National Agency for Medicines
and from the Institute for Medical Statistics and the units (packages) sold were calculated to indicate
the number of courses as follows: one course of CC means 100 mg of CC daily for 5 days, that of
hMG/FSH 150 IU of FSH daily for 10 days, and one cycle of OC the use of OC for 28 days (Table 12).
1.2. Study II
The reproductive histories of patients with GCT were analysed among a group of 146 patients with
GCT diagnosed at Helsinki University Central Hospital during the 40-year period 1956 - 1996 (Table
12).  The data included 14 patients with mixed granulosa-theca cell tumours with a clear granulosa cell
component. The staging of the tumours was standardized according to FIGO criteria (ACOG, 1992).
Menstrual history, occurrence of infertility, use of any hormones and clinical symptoms were recorded
from the patients´ charts. The reproductive characteristics of patients with GCT at a fertile age (from 16
to 45 years, n=50) were compared with those who had GCT later in life (from 46 to 75 years, n=96). In
addition, the subgroup of patients who had been at a fertile age since 1966 and could have been users of
ovulation inducers (n=41) was analyzed separately.  The results concerning fertility were compared
with the data of the two population–based databanks (Table 12) on fertility features in Finland in
general (Nikander, 1992) or among women participating in the Pap screening programme in Helsinki
(Rantala and  Koskimies, 1986).  The age of menarche and body mass index were compared to national
averages (Widholm and Kantero, 1971; Pietinen et al., 1996).
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1.3. Studies III-V
The entire study population consisted of 71 consecutive patients, who were infertile because of either
tubal occlusion (n=31), endometriosis (n=10) or some unknown cause(s) (n=30) and who took part in
their first IVF treatment at our clinic (Study V). Subgroups of 37 (Study III), and of 69 (Study IV) of
the original 71 infertile patients were investigated for VEGF and leptin, respectively (Table 12). For the
VEGF analysis (Study III), patients with term pregnancies and patients for whom 4-6 serum samples
were available so that at least one sample was taken after OPU, were included randomly.  The
subgroup for leptin analysis included all patients with OPU who had 4 (n=2), 5 (n=8 ) or 6 (n=51)
serum samples for analysis (Study IV).
The relevant clinical characteristics, such as weight, height, parity, medications, smoking and
family history of cancer were recorded. In study IV the patients with a BMI of less than 19.4 kg/m2
were classified as “underweight”, those with a BMI between 19.5 kg/m2 to 26.5 kg/m2 as “normal
weight”, and those with a BMI of 26.5 kg/m2 or more as “overweight”(Bianco et al., 1998).
The control population consisted of 10 healthy women (Study III), who did not use any
hormonal contraceptives, intrauterine device or medication.  In study V, one of the original 10 control
women was excluded because of her apparent infertility (Table 12).  The distribution of patients and
controls among the various study groups is described in detail in the original papers.
Table 12.  Study subjects (data given as mean ± standard deviation).
                                                                                                                                                                 
Patients, Controls, Materials Source of         No. of Time Age, Body Mass
by Study                                             Data                                               Subjects   Period             years   Index , kg/m2  
I   a) Females with GCT Finnish Cancer Registry       590 1965 - 1994 all ages   NA
    b) Females with ovarian cancer Finnish Cancer Registry           12650 1965 - 1994 all ages   NA
    c) Sales statistics of ovulation National Agency for Medicines       - 1981 - 1994  -      -
     inducers and oral contraceptivesInstitute for Medical Statistics       - 1965 - 1994  -      -
II  a) Patients with GCT HUCH, Dept. Obst. & Gyn.   146 1956 - 1996 53.0±15.3  25.6±4.9
    b) Nikander, 1992   Population study, Finland                5105 1989            22 - 55     NA
    c) Rantala & Koskimies, 1986 Pap screening, Helsinki area           4710 1982          30, 35, 40  NA
III a) Infertile women and IVF HUCH, Dept Obst. & Gyn.       37 1995 - 1996  32.9±4.1   23.4±4.1
    b) Healthy controls volunteers     10 1996           35.3±4.7   21.7±2.7
IV Infertile women and IVF HUCH, Dept Obst. & Gyn.        69 1995 - 1996  33.2±3.9   22.9±3.6
V  a) Infertile women and IVF HUCH, Dept Obst. & Gyn.     71 1995 - 1996  33.3±3.8   23.0±3.5
    b) Healthy controls                       volunteers                                                9    1996             34.8±4.9   21.4±2.8     .
GCT: granulosa cell tumour; Dept. Obst. & Gyn.; Department of Obstetrics and Gynaecology, HUCH: Helsinki University
Central Hospital; IVF: in vitro fertilization programme; NA: not available
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2. PROTOCOL
2.1. Ovarian stimulation protocol
The IVF programme consisted of long pituitary down-regulation with a GnRH agonist (nafarelin,
Synarela®, Syntex, Södertälje, Sweden) which was initiated at a daily dose of 800 µg during the
approximated midluteal phase of a preceding spontaneous menstrual cycle. The phase of the cycle was
determined by calculating midluteal phase from the known length of previous menstrual periods and
the luteal phase was confirmed by a transvaginal ultrasound finding of a secretory endometrium and
absence of follicles, or presence of a corpus luteum.  In the presence of ovarian suppression (defined as
a double-layer of endometrium • 5 mm thick, and serum E2 concentrations of less than 0.1 nmol/L), the
dose of the GnRH agonist was halved and ovarian stimulation was started by giving randomly either
urinary gonadotrophins (Humegon® n=15, Organon, Oss, the Netherlands, or Pergonal® n=19,
Laboratories Serono S.A., Aubonne, Switzerland, containing equal amounts of FSH and LH) or
purified urinary FSH (Fertinorm HP® n=16, Laboratories Serono S.A., or Follegon® n=19, Organon)
at a daily dose of 150 IU (n=58) or 225 IU (n=11).  The dosage was adjusted after the first 5 days
according to the ovarian response.  Human chorionic gonadotrophin (Pregnyl®, Organon) was injected
(10 000 IU) when at least three follicles exceeded 16 mm in diameter.  A transvaginal OPU was
performed 36 hours later.  Ova were fertilized in vitro, and a maximum of two embryos were
transferred 2 (n=48) or 3 days (n=11) after OPU. In four patients, fertilization failed to produce any
embryos , and in an additional four patients, ET was not done because of predictive signs of OHSS
(serum E2 • 15 nmol/L and the presence of more than 20 follicles). After ET, 600 mg of micronized
progesterone (Lugesteron®, Leiras, Turku, Finland) was given daily intravaginally for 2 weeks. A
consistently rising hCG level was judged to indicate clinical pregnancy, whereas a transient rise in hCG
followed by profuse bleeding within 2 weeks was regarded as a subclinical abortion (Table 17).  If
pregnancy was not achieved, the patient was asked to come for a follow-up visit in the follicular phase
(pd 8-10) of her second menstrual cycle after IVF, when her ovaries and uterus were investigated by
transvaginal ultrasound (Study V).
2.2. Timing of blood sampling and assays used
Before, during and after ovarian stimulation, frequent blood samples were collected in the morning
after an overnight fast, as indicated in Table 13.  The blood sample taken prior to IVF treatment
(sample I) is called "baseline or basal" in the IVF patients.  In addition, eight random patients (four
with tubal occlusion and four with unexplained infertility) provided blood samples every second or
third day during treatment with a GnRH agonist to permit a study of the effect of ovarian suppression
on the levels of pituitary hormones (Study V).  Ten healthy control women provided blood samples
every second or third day during one menstrual cycle (10–14 samples per subject). The day of
ovulation in the menstrual cycle was determined from the LH surge and progesterone rise. The cycle
was divided into the menstrual phase (days from –15 to  -9, n = 21 samples), the follicular phase (days
-8 to -3, n = 20), the periovulatory phase (ovulation ± 2 days, n=17), and the luteal phase (days +3 to +
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14, n = 40).  The assays used are described in Table 14. The conversion factor for E2 was 1 pmol/L =
3.671 pg/mL, and that for progesterone 1 nmol/L = 3.180 ng/mL.
3. STATISTICAL ANALYSES
Variables that were not normally distributed by the Kolmogorov-Smirnov normality test were
logarithmically (log10) transformed for parametric testing.  Comparisons between groups were
performed with the chi square test (categorical variables), Student's two-tailed unpaired t test
(continuous variables, two groups), analysis of variance (ANOVA, continuous variables, several
groups) or analysis of covariance (ANCOVA).  For within-group analysis, Student's two-tailed paired t
test or repeated measures analysis of variance with Fisher's PLDS (Study IV) or with the Bonferroni-
Dunn post hoc test were used (Study V).  Relations between continuous variables were calculated with
linear or multiple regression.  A P value of < 0.05 was considered significant.
Table 13.  Timing of collection of blood samples during the in vitro fertilization programme in
     studies III-V.
                                                                                                                                                            
Blood Study III Study IV Study V
sampling
Number          Time (mean ± SD)                            VEGF             Leptin     Tumour markers    
I Prior to start of GnRH agonist 37 66 71
(cycle day 22.3 ± 0.3)
II At ovarian suppression 37 66 69
III After 4 to 5 days of ovarian stimulation 69
IV 3 to 5 days before OPU 21 62 62
V At OPU 37 66 67 
VI At ET, 2 to 3 days after OPU 66
VII 5 to 6 days after OPU 31
VIII 8 to 9 days after OPU 20 64 63
IX 10 to 12 days after OPU 30
X 14 days after OPU 36 60 60
XI Second cycle after IVF 42
            (cycle day 9.6±1.8)                                                                                                               
ET: embryo transfer; GnRH: gonadotrophin-releasing hormone; IVF: in vitro fertilization programme;
OPU: ovum pick-up; SD: standard deviation; VEGF: vascular endothelial growth factor
45
Table 14.  Characteristics of assays used.
                                                                                                                                                                                                
Factor Principle of assay Source of reagents Intra- and interassay CV%
                                                                                                                                               (in the concentration range   )
CA 125 Immuno1®immunoanalyser Bayer Corp., Tarrytown, NY, USA  < 4 (15-490 kU/L)
OC 125 and M 11 antibodies Centocor, Malvern, PA, USA
FSH Fluoroimmunoassay, DELFIA, Wallac, Turku, Finland  < 3  (2.6-44.5 IU/L)
AutoDELFIA™
GPHα Fluoroimmunoassay in-house method1 < 10  (10-1000 pmol/L)
hCGβ Fluoroimmunoassay in-house method2 < 10  (1.0–5000 pmol/L)
hCG dimer Fluoroimmunoassay DELFIA  < 8 (7-940 IU/L)
Leptin RIA Linco Research, St.Charles, USA  < 5 (2.8-15.6 µg/L)
LH Fluoroimmunoassay, DELFIA  < 4  (0.3–42.0 IU/L)
AutoDELFIA™, “LHspec”
Oestradiol RIA Orion Diagnostica, Espoo, Finland  < 9 (0.4-9 nmol/L)
Progesterone RIA Orion Diagnostica < 10  (2.1–45 nmol/L)
TATI RIA Orion Diagnostica < 11 (1-60 nmol/L)
TSH Fluoroimmunoassay, Ciba Corning, Halstead, Essex, UK  < 7 (0.6-26 mIU/L)
ACS:180 autoanalyser
VEGF             EIA, Quantikine™                            R&D Systems, Abingdon, UK        <   9    (15-2000 pg/mL)       
CV: coefficient of variation; EIA: enzyme immunoassay; FSH: follicle stimulating hormone;
GPHα: common α-subunit of glycoprotein hormones; hCG: human chorionic gonadotrophin;
LH: luteinizing hormone; RIA: radioimmunoassay; TATI: tumour-associated trypsin inhibitor;
TSH: thyroid-stimulating hormone; VEGF: vascular endothelial growth factor;
1
 Alfthan et al., 1988; 2 Korhonen et al., 1997
46
0
10
20
30
40
1970 1980 1990 2000
year
clomiphene 
citrate
hMG
10
12
14
0
0.25
0.50
0.75
1.00
1965-69 70-74 75-79 80-84 85-89 90-94 95-99
years
GCT
ovarian 
malignancies
0
1000
2000
3000
1960 1970 1980 1990 2000
year
combined contraceptive
pills
Figure 6. Incidence of ovarian malignancies and 
granulosa cell tumour (GCT) in 5-year periods as well
as the number of annual courses of clomiphene citrate,
human menopausal gonadotrophins (hMG) and 
combination contraceptive pills in Finland in 1965-94.
  
Table 15.  Incidence and number of ovarian granulosa cell 
tumours in Finland in 1965-94 by 5-year periods and age.
                                                                                               
Time Incidence / 100,000 in age groups, years             
period <15 15-29 30-44 45-59 60-74  75
 No.
                                                                                                
1965-69   0.07 0.29 0.54 2.19 2.16 1.60 108
1970-74   0 0.26 0.95 2.06 2.47 0.93 122
1975-79   0.04 0.20 0.93 2.13 1.47 1.50 109
1980-84   0.04 0.10 0.56 1.60 1.44 0.76   81
1985-89   0 0.02 0.56 1.41 1.21 1.84    84
1990-94   0.09 0.08 0.64 0.84 0.84 0.62
   86
                                                                                                 
Total   0.04 0.16 0.67 1.71 1.78 1.21
No. (%)    6 (1)    30 (5)    103 (17)  216 (37)  186 (32)   49 (8)         590 (100 )
                                                                                                  
No.: number
The incidence of GCTs rose from 0.74 /
100,000 women in 1965-69 to 0.82 / 
100,000 in 1970-74, but thereafter the 
incidence fell by 40% to 0.47 / 100,000 
women in 1985-94 (Figure 6). At the 
same time, the consumption of CC 
increased 13-fold from 1966 to 1988. 
Gonadotrophins (hMG, FSH) were used 
minimally up to the late 80s, after which 
their use showed a sharp 200-fold rise.  
At the same time the incidence of all 
ovarian malignancies, including GCT, 
rose by 28% from 10.6 / 100,000 to 13.6 
/ 100,000, although the use of combined 
OCs steadily increased from the 1980s to 
the 90s, showing a 5-fold rise since 1966.  
The decrease in the incidence of GCTs 
occurred mainly in women aged 15 to 29 
and in those aged 45 to 74 years 
(Table 15).
V RESULTS
1. INCIDENCE OF GRANULOSA CELL TUMOUR IN FINLAND (Study I)
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2. REPRODUCTIVE FEATURES OF PATIENTS WITH GRANULOSA CELL TUMOUR
   (Study II)
Of the 146 women studied, 50 had GCT diagnosed at a potentially fertile age (Table 16), and 118 after
the introduction of ovulation inducers in 1966. The age at diagnosis for all cases ranged from 16 to 87
years, with a mean age of 53.0 years. The majority of GCTs (82%) occurred in women between 35 and
75 years of age and over half of the patients were postmenopausal (56%), the median time from
menopause to GCT diagnosis being 13 years (range 0 - 36).   Four women (5%) had reached the
menopause before the age of 40.
The age at menarche (range 10 - 18 years) was comparable to the national average if GCT
occurred at a fertile age, but the frequency of nulliparity was almost twice as high as in Finland
generally (Table 16).  If GCT was diagnosed after the fertile age, the range of ages at menarche was
similar, and over half of the patients were multiparous (53%), corresponding to the national average. In
the GCT series as a whole, three women (2%) were pregnant at the time of GCT diagnosis, whereas 12
women (9%) had experienced infertility, mainly anovulatory infertility (58%).  The frequency of
primary infertility was high in the women with GCT at a fertile age (23%), as the national average was
9%.  Of the infertile women, five had used fertility drugs for 1 to 10 months, but none had participated
in an IVF programme.  Thus the frequency of users of ovulation inducers was 4.2% (5/118).  The
tumours in women with a history of use of ovulation inducers were detected at stage I and mostly
within a year after the first use of an ovulation inducer. After removal of the tumour, all five women
became pregnant normally. The number of patients with GCT at a fertile age showed no increase
during the four decades studied (24% in 1956-66, 28% in 1967-76, 22% in 1977-86 and 26% in 1987-
96).
The most common gynaecological symptom of GCT at a fertile age was oligo-amenorrhea
(45%) whereas the most common symptom at an older age was dysfunctional bleeding (71%).
Hyperplasia of the endometrium was encountered in all age groups, but was more frequent if GCT was
diagnosed after the age of 45 (Table 16). Cancer of the endometrium was detected only in patients with
GCT after the fertile age.
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Table 16. Reproductive characteristics and endometrial histology of 146 patients with a granulosa cell
tumour in relation to fertile age (• 45 years). The population-based data (PBD) are given for reference
with corresponding age-adjusted data of the current series.
                                                                                                                                                                 
•45 years > 45 years Total Data Subgroup2 PBD
 50 (34) 96 (66) available
                                                            No. (%)           No. (%)                                   No. (%1)          No. (%)           No.(%)
Menarche (mean, years) 13.4 14.4 14.0 114 (78) 13.2a
Age at diagnosis (median, years) 37.0 61.0 54.0 146 (100)
Body mass index (mean, kg/cm2) 24.8 26.0 25.6 142 (97) 25.5, 25.1b
BMI  •30                                            6 / 48 (13)      16 / 94 (17)    22 (15)                                   11 / 86 (13)    14%b   
Parity, No. 50 92 142 (97) 62 
Mean parity 1.1 2.0 1.7 1.3 1.8c
Nulliparous 25 (50) 21 (23) 46 (32) 27 (39) 24% c
Primiparous   9 (18) 22 (24) 31 (22) 11 (18) 17% c
Multiparous 16 (32) 49 (53) 65 (46) 27 (44) 59% c
Infertility 11 / 48 (23) 1 / 88  (1) 12   (9) 135 (93)  -
age <40, primary infertility  7 / 31 (23 )  9% c2
            age 30-40, total infertility                                                                                                    6 / 26 (23)      15% d   
Histology of the endometrium, No. 41 86 127 (87)
Endometrial hyperplasia   8 (20) 30 (35) 38  (30)
Endometrial polyp    3  (7) 11 (13) 14  (11)
Adenomatous hyperplasia   1  (2) 10 (12) 11   (9)
Cancer   -   (-) 10 (12) 10   (8)
Pregnancy   3  (7) -   3   (2)
            Normal                                   26 (63)           25 (29)           54  (42)                                                                      
No.: number; 1 percentages calculated from the data available; 2 analysis of the same age groups as the reference. Subgroups in the GCT
series corresponding to the age group of the reference study: Pietinen et al., 1996 (n=86; age 30-59 years in our series); Nikander, 1992
(n=62; age 22-51 years in our series); Nikander , 1992 (n=31; age<40 years in our series); Rantala and Koskimies, 1986 (n=26; age 30-40
years in our series)
aWidholm and Kantero, 1971 (n=8111 girls, 10-20 years in 1969); bPietinen et al, 1996 (n=734, 30-59 years
in Helsinki area in 1992); cNikander, 1992 (n=4155, 22-51 years in 1989); c2Nikander, 1992 (n=836 nulliparous <40 years); dRantala and
Koskimies, 1986 (n=4202, 30, 35 or 40 years in 1982).
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3. STUDIES ON IN VITRO FERTILIZATION CYCLES AND ON VERY EARLY
    PREGNANCY
In all, 71 cycles with controlled ovarian hyperstimulation were studied. Of them, four patients failed to
become stimulated so 67 patients finally underwent OPU.  Embryo transfer was performed in 59
patients, because the programme failed to produce transferable embryos in four women and an
additional four patients experienced no ET because of signs of severe OHSS (Table 17).  All the
patients were treated at the outpatient clinic. Of the 59 patients with ET, 18 (31%) achieved clinical
pregnancies, 13 delivered at term (22%), and three of them had twins (23%).  Of the 49 patients not
achieving pregnancy, 42 (79%) participated in the follow-up study 2 months after IVF treatment. The
patients undergoing IVF and normal cycles were comparable in regard to age, BMI, and pre-treatment
FSH level (Tables 12 and 17).
Table 17. Clinical characteristics (mean ± SD) of the study populations.
                                                                                                                                                                                    
Total Causes of infertility                                      Controls
series Tubal Pelvic Unexplained 
                                                                        occlusion        endometriosis  infertility                                          
Patients beginning GnRHa        71        31       10       30         9
Basal FSH (IU/L) 1    5.9 ± 2.0   6.0 ± 1.7   5.7 ± 1.2   6.0 ± 2.7   5.8 ± 1.8
Ovarian suppression (days) 16.6 ± 4.7 15.8 ± 2.1 16.5 ± 2.9 17.4 ± 6.7
Patients beginning hMG        69        30          9        30
  - duration (days) 10.7 ± 1.4 10.9 ± 1.1 10.2 ± 1.0 10.7 ± 1.7
  - gonadotrophin use (IU) 2002 ± 639 1955 ± 553 1933 ± 613 2070 ± 734
Maximal oestradiol (pg/mL)1202 ± 1202 1453 ± 1589 1335 ± 1195   986 ± 594  182 ± 85 *
      (nmol/L)    4.5 ±  4.4    5.3 ± 5.8    4.9 ± 4.4    3.6 ± 2.2   0.7 ± 0.3
Patients with OPU              67               29                 9        29
Number of follicles 16.1 ± 8.6 16.7 ± 9.7 18.0 ± 8.4 15.0 ± 7.5
Number of oocytes 11.4 ± 6.3 11.8 ± 7.1 12.9 ± 6.8 10.5 ± 5.4
Fertilization (%)     53 ± 27    61 ± 26    51 ± 27    44 ± 25
Patients with ET        59               25                 7        27
Progesterone2 (ng/mL) 21.2 ± 19.3  23.3 ± 25.3  19.4 ± 11.5  22.9 ± 17.0    12.0 ± 4.6
           (nmol/L) 69.7 ± 62.7  70.5 ± 76.6  58.7 ± 34.9  72.2 ± 53.1    37.6 ± 15.6
Subclinical abortion   5              1               -    4
1st trimester miscarriage   5              4               -    1
Delivery 13              6              2              5
Patients with follow-up3             42                   17                     7                   18                                                
BMI: body mass index; ET: embryo transfer; FSH: follicle-stimulating hormone; GnRHa: gonadotrophin-releasing
hormone agonist; hMG: human menopausal gonadotrophin; OPU: ovum pick-up;
1
 early luteal phase of a normal cycle prior to treatment 2 8 days after OPU / controls: 8 days after ovulation
3
 follow-up visit 2 months after in vitro fertilization programme
* p < 0.05; no other comparisons between different groups were significant (ANOVA)
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3.1. Vascular endothelial growth factor (Study III)
Prior to IVF treatment, the midluteal VEGF levels in serum ranged from 10 pg/mL to 679 
pg/mL.  No differences were observed in the serum levels between the different infertility 
groups or between the IVF patients and the control population.  
IVF Cycle: Ovarian suppression did not affect VEGF levels in serum. However, preceding and 
following OPU, the serum VEGF levels rose and were significantly higher at 8-9 days after 
OPU (range 31-796 pg/mL)  as compared with those in the controls or with those during the 
midluteal phase prior to IVF treatment in the same patients. (Figure 7) 
Midluteal pretreatment VEGF was related to the BMI (r = 0.53, P < 0.01) and to the 
progesterone (r = 0.53, P < 0.05), and these two factors explained 40% of the midluteal 
increase in the VEGF level. When the IVF patients and the controls were pooled, the midluteal 
VEGF correlated with the peak follicular phase E2 (r =0.40, P <0.05) and with progesterone at 
the luteal phase (r=0.43, P < 0.05).  
Very early pregnancy:   The IVF-induced rise in the VEGF level was seen both in the women 
who became pregnant and in those who failed to do so.  At 12 days after ET, the mean levels of 
VEGF seemed to be higher in patients with term pregnancies (range 64 - 823 pg/mL) than in the 
non-pregnant patients (range 20 -487 pg/mL), but the difference was not significant. (Figure 7, 
at lower right) 
Normal cycle: Concentrations of VEGF ranged from 23 pg/mL to 389 pg/mL.  No cyclicity in 
VEGF could be detected (Figure 7).  The levels of VEGF were independent of age, BMI, or the 
levels of FSH, E2, or progesterone.
Figure 7. Serum vascular endothelial growth factor (VEGF) levels (mean±SE) in 
37 infertile women undergoing an IVF programme and in 10 healthy women with ovulatory 
cycles.  * P <0.05 between cycles, other P values refer to IVF cycles.
At upper right are the levels of VEGF in IVF cycles with respect to cause of infertility and at 
lower right those with respect of pregnancy result; number of patients in parentheses.  
I midluteal phase of the previous cycle 
II ovarian  suppression A day 2-4 of menstrual bleeding 
III 3-5 days before ovum pick-up (OPU) B 2-3 days before ovulation
IV day of OPU C  day of ovulation
V 8-9 days after OPU D  8-9 days after ovulation
VI 12-14 days after OPU E 11-14 days after ovulation
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3. 2. Leptin (Study IV)
Basal leptin levels correlated strongly with BMI (r= 0.85, P < 0.0001), Accordingly, the levels were
lower in patients who were underweight (6.4 ± 0.8 µg/L, range 3.1-11.9 µg/L) than in those with
normal weights (12.0 ± 0.7 µg/L, range 5.0-25.3 µg/L, P <0.01), or in those who were overweight (25.7
± 2.8 µg/L, range 15.5-39.3 µg/L, P < 0.0001).  The difference in leptin between the normal and the
overweight groups was significant (P < 0.0001).  Basal leptin levels in unexplained infertility (12.1 ±
1.5 µg/L), in endometriosis (13.1 ± 3.0 µg/L), and in tubal occlusion (14.0±1.3 µg/L) did not differ
significantly. Neither age (•35 years / > 35 years), type of infertility (primary / secondary), nor smoking
(yes/no) were significant factors for basal leptin levels. When all the patients were considered as a
single group, both serum E2 (r = 0.16, P = 0.01) and BMI (r = 0.89, P < 0.001) were significant factors
for the midluteal phase leptin level.
IVF cycle: Ovarian suppression was associated with a fall in leptin of 21 ± 4% (P < 0.01) (Figure 8).
This did not correlate with falls in LH (46 ± 5%) or E2 (91 ± 1%).  Relatively, the fall in leptin seemed
higher in the patients with normal weight (21 ± 4%) or overweight (26 ± 7%) than in the underweight
patients (12 ± 10%), but the differences between these changes were not significant. When E2
production was suppressed (E2 < 0.1 nmol/L), E2 correlated positively with leptin (r = 0.20, P = 0.01).
Ovarian stimulation was followed by significant increases in leptin concentrations (Figure 8). After 4
to 5 days of ovarian stimulation, this rise was on average 45 ± 6% and reached a maximum of 76 ± 8%
at the time of OPU. A rise of 20% or more in leptin occurred during stimulation in 56% of the
underweight patients, in 83% of those with normal weight and in every overweight patient (P < 0.05).
No linear relation existed between daily serum leptin and E2 or progesterone during ovarian
stimulation, or between leptin and the number of ovarian follicles. The rise in leptin during stimulation
with human menopausal gonadotrophin (containing LH) (90 ± 11%) did not differ significantly from
that induced with purified FSH (62 ± 10%) (P = 0.07). The increases in leptin during ovarian
stimulation were similar in all types of infertility (Figure 8).
Luteal phase: In the presence of high progesterone (69.7 ± 7.8 nmol/L) 8 days after OPU, the leptin
levels were similar to those seen at OPU (Figure 8).  The level of leptin did not correlate with that of
progesterone but correlated positively with E2 (r=0.17, P < 0.05). The midluteal level of leptin after
ovarian stimulation (16.5 ± 1.5 µg/L) was 28 ± 7% higher than at the same phase of a normal cycle
prior to IVF treatment (13.1 ± 0.9 µg/L, P < 0.001).
Very early pregnancy: Twelve days after ET, when endogenous hCG becomes detectable if pregnancy
occurs, the level of leptin fell (P < 0.01; Figure 8). The relative decrease in leptin levels from OPU to
14 days after OPU (i.e. 12 days after ET) tended (P = 0.06) to be larger in women failing to become
pregnant (25 ± 4%) and in those with miscarriages (27 ± 7%) than in women whose pregnancies were
successful (8 ± 6%; Figure 8). A successful outcome of pregnancy was associated with a higher level
of leptin in the first days of gestation (18.7 ± 4.8 µg/L; Figure 8) than in those experiencing a first
trimester miscarriage (10.0 ± 1.9 µg/L, P < 0.001), a subclinical abortion (11.5 ± 3.4 µg/L, P < 0.05), or
no implantation (11.6 ± 1.2 µg/L, P < 0.0001). In the three women with twin pregnancies, the leptin
levels (20.4 ± 1.9 µg/L) were comparable with those seen in single pregnancies (18.2 ± 6.3 µg/L). hCG
was not an independent factor for leptin (r = 0.12, P = 0.08).

                                                                                                             
-50
0
50
100
150
200
250
300
350
0 2 4 6 8 10 12
Y = -1.431 + .06 * X; R2 = 48%
r = 0.69
P = 0.001
n = 18
Clinical pregnancy
                                                                                                             
-50
0
50
100
150
200
250
300
350 r = - 0.10
P = ns
n = 41
R2 = 1%
No pregnancy
E2max,  x103 pmol/L
BMI  27
BMI 20-26
BMI Š 19
1st trimester miscarriage
0 2 4 6 8 10 12
Figure 9. Relations between rises in leptin and peak oestradiols (E2max)  during ovarian 
stimulation in women who became clinically pregnant as a result of IVF treatment and 
those failing to do so.
Correlations: Patients who became pregnant as a result of the treatment showed a 
significant correlation between the ovarian stimulation-induced rise in leptin and the 
maximal E2 value (Figure 9). Similarly, patients with pregnancies showed positive 
correlations between the rise in leptin and the number of follicles (r=0.62, P = 0.006), and 
the oocyte count (r = 0.74, P < 0.001), and a marginal correlation with progesterone at 
OPU (r = 0.46, P = 0.05). 
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3.3. Tumour markers (Study V)
3.3.1. Cancer antigen 125
Prior to IVF treatment, the midluteal level of CA 125 was significantly higher in patients with
endometriosis than in the other groups (Figure 10). Four of the patients with endometriosis had levels
exceeding the upper normal limit of 35 kU/ml in clinical practice (range 61-109 kU/L) (Bidart et al.,
1999).
IVF cycle:  Ovarian suppression caused a 36% (CI95% 19, 54) increase in CA 125 levels (Figures 10 and
11). This rise was higher (mean 98%, CI95% 8, 189) in the 11 patients with bleeding at verified
suppression than in those without bleeding (24%, CI95% 11, 38, P < 0.01).
Ovarian stimulation was followed by a decrease in CA 125 to the basal level (Figure 10) and this was
unaffected by discontinuation of the GnRH agonist or by injection of hCG.
During the luteal phase, CA 125 levels increased significantly above the starting values (mean rise
114%, CI95% 57, 171). The relative increase in CA 125 appeared greatest in women with tubal occlusion
(Figure 11).
Very early pregnancy:  Fourteen days after OPU, the CA 125 levels in 18 pregnant women (median 36
kU/L, CI95% 27, 70) did not differ significantly from those in non-pregnant women (24 kU/L, CI95% 19,
36; Figure 13).
Two months after IVF:  The CA 125 levels were significantly higher (17 kU/L, CI95% 14, 25) than the
pre-treatment levels (15 kU/L, CI95% 11, 21; P < 0.01; Figure 11).  The median difference between the
levels was 12%, ranging from a decrease of 50% to an increase of 234%.  The Ca 125 levels exceeded
the 35 kU/L (range 54-203 ku/L) in seven (17%) patients of whom five were infertile on account of
endometriosis but two because of unexplained causes. Of these seven patients, three were shown to
have ovarian endometriomas and one a dermoid cyst, as evidenced by pelvic ultrasound examination
and later by surgery.
Correlations:  The basal CA 125 level correlated inversely with BMI (r = - 0.32, P < 0.01). At OPU,
CA 125 correlated with E2 (r = 0.28, P < 0.05) and at the time of ET both with E2 (r = 0.40, P < 0.01)
and progesterone (r=0.47, P < 0.0001).  At 8 days after OPU, CA 125 correlated with E2 (r = 0.44, P <
0.01), with the number of follicles (r = 0.56, P < 0.0001) and with progesterone (r = 0.26, P < 0.05).
Normal cycle:  The Ca 125 level was higher during the menstrual phase.  The mean relative increase
from the midluteal phase level to the peak level was 34% (CI95% –3%, 72%).
3.3.2. Tumour-associated trypsin inhibitor
No significant cyclicity in the serum levels of TATI occurred during either the IVF cycles or the
normal cycles; neither infertility, pregnancy nor IVF treatment affected the levels of TATI in serum.
(Figures 10, 11 and 13).
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 Figure 10.  Serum concentrations of CA 125, tumour-associated trypsin inhibitor (TATI), free
 
β-subunit of hCG (hCGβ), and free glycoprotein hormone α-subunit (GPHα) before, during, 
and 2 months after IVF treatment with long downregulation followed by ovarian stimulation 
with urine-derived FSH. The arrow indicates injection of hCG (10 000 IU) 36 hours prior to
ovum pick-up (OPU).The boxes show the quartiles (25th and 75th percentiles) and the median.
Whiskers extend to the 10th and 90th percentiles. Outliers not shown.
ANOVA for repeated measurements with the Bonferroni-Dunn post hoc test (log10-data) * P Š 0.001, ** P < 
0.0001, - not significant  (solid line: I, II, III, IV,V,VI,VIII, X included), (---: I, II, III, IV, V,VI,VIII, X, XI 
included for comparison between I and XI). 
Timing of sampling:
I: Midluteal phase of prior spontaneous menstrual cycle, (n=71)
II: Ovarian suppression  (n=69) 
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     
III: Gonadotrophin used for 3-5 days, (n=69)
IV: 3-5 days prior to OPU (n=68)
V: OPU (n=67) 
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VI: Embryo transfer (n=66)
VII: 5-6 days after OPU  (n=32)
VIII: 8 days after OPU (n=65)
IX: 10-11 days after OPU (n=30) 
X: 14 days after OPU (n=61) 
R: Midfollicular phase 2 months after IVF (n=42) 
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Figure 11. Mean percentage changes  (± 95 % confidence limits) in serum  CA 125, 
tumour-associated trypsin inhibitor (TATI), β-subunit of human chorionic 
gonadotrophin (hCGβ) and free glycoprotein hormone α-subunit (GPHα), from the 
midluteal phase level of the preceding cycle during an IVF programme and 2 
months after IVF, and during normal menstrual cycle in controls.  Roman numerals 
indicate the timing of blood samples, see Figure 10.
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3.3.3. β-subunit of human chorionic gonadotrophin
Basal hCGβ levels ranged from undetectable to 2.7 pmol/L and the levels were unaffected by
infertility. IVF Cycle: Ovarian suppression / stimulation had no effect on hCGβ levels until injection of
hCG, which caused a 40% rise in hCGβ . The hCGβ then fell to a normal level within a week after
injection. (Figures 10 and 11)
Very early pregnancy: In patients becoming pregnant, the levels began to rise already at 10 to 12 days
after OPU (sample IX, Table 13). The median level was 0.8 pmol/L (CI95% 0.5, 6.2) in patients with
clinical pregnancies and 0.4 pmol/L (CI95% 0.4, 1.31) in non-pregnant patients.  At 14 days after OPU
the levels of hCGβ were significantly higher in all pregnant patients than in non-pregnant patients,
however, successful pregnancies could not be differed from miscarriages (Figure 13).
Two months after IVF: The levels of hCGβ were similar to the pre-treatment levels.
Normal cycle: No significant variation occurred in hCGβ.
3.3.4. Common free α-subunit of glycoprotein hormones
The basal level of GPHα (Figure 3) were unaffected by infertility, but correlated with LH (r = 0.94, P <
0.0001).
IVF cycle: The start of ovarian suppression with the GnRH agonist induced a rapid rise in GPHα
levels, which remained elevated during the entire suppression phase.  This was specific for GPHα,
because hCGβ and TSH were unaffected and LH and FSH declined after an initial rapid flare-up
(Figure 12). The relative increase in GPHα during the suppression phase was 1680%, (CI95% 1396,
1966) and this rise was greater (P < 0.01) in the patients without bleeding (1800%, CI95% 1497, 2102)
than in those with bleeding (747%, CI95% 282, 1211).
Ovarian stimulation did not affect the levels of GPHα, whereas discontinuation of the GnRH agonist
and simultaneous injection of hCG caused a rapid decrease in GPHα (Figures 10 and 11).  
Very early pregnancy: At 14 days after OPU, the GPHα levels were significantly (P < 0.01) lower
(median 9 pmol/L, CI95% 8,12) than those in the non-pregnant patients (median 20 pmol/L, CI95% 17, 24).
(Figure 13)
Two months after IVF: In all the infertile patients the post-treatment follicular phase GPHα was
significantly higher (median level 25 pmol/L, CI95% 23, 30) than the pre-treatment luteal phase level of
GPHα (17 pmol/L, CI95% 10, 24, P < 0.0001) but comparable with the follicular phase level of normal
menstrual cycles of the controls (Figures 10 and 11).
Normal cycle: GPHα peaked prior to the LH surge (Figure 11). The mean relative increase from the
midluteal phase level to the peak level was 373% (CI95% 181, 566; Figure 11).
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Figure 12. The effect of ovarian suppression with a GnRH agonist (nafarelin) on the serum levels 
of FSH, LH, TSH, hCG β and GPHα in 8 infertile women.
 Anova for repeated measurements * P < 0.01, ** P < 0.0001  Bonferroni Dunn post hoc test
Timing of sampling: I midluteal phase, cycle day 21.4 ± 2.2 (mean ± SD) start of the GnRH agonist, a = 2±1 days, 
b = 4 ± 1 days, c = 7 ± 0.4 days, d = 12 ± 1 days, II = ovarian suppression, 16 ± 3 days use of GnRH agonist.
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Figure 13. Distribution of CA 125, tumour associated trypsin inhibitor (TATI) , free β-subunit 
of human chorionic gonadotrophin (hCGβ) and free glycoprotein hormone α-subunit (GPHα) 
in 59 women 12 days after embryo transfer with reference to pregnancy outcome. 
 
* p < 0.0001 ANOVA, all comparisons for hCG β, for GPHα between successful pregnancy and no pregnancy. 
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VI DISCUSSION
Infertility in western populations is on the rise, and this indicates an enhanced need and resources for
infertility treatments in future (Mosgaard et al., 1995; Chandra and Stephen, 1998; Raitio et al., 1998).
The willingness of a given infertile couple to use modern infertility treatments depends not only on the
efficacy of the treatments but also on the costs, convenience and possible risks of the treatment (Rosen
et al., 1997).  The risks of infertility treatments can be classified as immediate adverse events, which
vanish quite soon after the treatment, and long-term consequences, such as the possibility of a tumour.
The aim of these studies on ovarian GCT and IVF cycles was to gain new insight into the possible risks
of infertility treatments and the physiological changes induced by IVF treatment as practised in Finland
for some 20 years and at present.
1. Infertility, infertility treatments and granulosa cell tumour
In Finland the incidence of all ovarian cancers, including borderline tumours and tubal cancers, was
rising from 1965 to 1994 (Study I). Therefore the hypothesis was to see a rise in the incidence of GCT
during the study period also, especially as CC and gonadotrophins had been introduced concomitantly.
In fact, there was a 13-fold rise in the use of CC and a 200-fold rise in the use of FSH / hMG during the
study period, these rises being similar to those reported from the USA and Denmark (Wysowski, 1993;
Mosgaard et al., 1995). Nevertheless, during the same period the incidence of GCT decreased by 40%.
This fall occurred predominantly in women between 45 to 74 years of age, and in young women (age
15 -29 years).  These young women may account for the rise in the consumption of OCs and whether
the use of OCs reduces both GCTs and epithelial ovarian cancers is debatable.  Interestingly, no change
in the incidence was observed in women in the common childbearing age range, 30-40 years.
However, it has to be acknowledged that GCT is a rare tumour and its incidence may fluctuate over
quite a wide range without traceable cause-and-effect links. However, our study did not lend support to
the claim that ovulation inducers trigger the onset of GCT (Willemsen et al., 1993).
Among patients with a GCT, the overall infertility rate was 9% (study II), which is fairly normal
for the Finnish population. The frequency of nulliparity was similar to that seen in other large series on
GCT (Fox et al., 1975; Pankratz et al., 1978; Stenwig et al., 1979; Björkholm and Pettersson, 1980;
Ohel et al., 1983).  However, in patients with a GCT diagnosed at a fertile age, the rates of infertility
and nulliparity were significantly higher than those generally found in the Finnish population.  Further,
the frequency of anovulatory infertility was double that for the unselected Finnish population (Rantala,
1988) and further, after surgery, spontaneous pregnancies were frequent.  These figures imply that
ovulation inducers are unlikely to cause GCT, but that the cause of anovulatory infertility may be a pre-
existing GCT.  However, a stimulatory effect of ovulation inducers on the growth of a pre-existing
GCT is possible.  Furthermore, the present study found no increase in the frequency of GCT in females
of fertile age from 1956-66 to 1987-96, even though, during that time, the use of ARTs has increased
markedly.  These findings can be taken as further evidence that infertility treatments do not induce the
development of GCT.
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2. The effect of infertility, an in vitro fertilization programme and very early pregnancy
A number of biologically potential mediators take part in the regulation of ovarian physiology and thus,
also, in the physiology of the endometrium.  The physiology of the genital organs may be altered
during aggressive ovarian suppression/stimulation, both of which are essential parts of modern ART.
In the present series several of these possible regulators were studied before, during and after the IVF
regimen. The recruitment of a rather large number of ovulatory patients with different types of
infertility allowed also evaluation of the impact of the type of infertility on the midluteal levels of these
bioregulators during natural cycles and whether they responded to the IVF programme.  In interpreting
the results, it has to be taken into account that not only the ovaries, but also other organs producing
these compounds, became exposed to the wide fluctuations in gonadotrophins and sex steroids during
the IVF cycles.
2.1 ... on the angiogenetic factors, vascular endothelial growth factor and leptin in the serum
The pretreatment midluteal levels of VEGF were not affected by infertility.  During the normal
menstrual cycle the levels of VEGF remained unchanged, and this finding is in line with previous data
(Lee et al., 1997; Yamamoto et al., 1997b; Chung et al., 1998).  In accordance with a previous report
(Lee et al., 1997) our IVF programme led to significant elevations in serum VEGF during the luteal
phase.  The elevated level of VEGF may derive from the granulosa cells, corpora lutei, endometrial
cells, or other sites capable of producing VEGF (Antczak et al., 1997; Geva and  Jaffe, 2000).  As
shown by in vitro and in vivo studies, it is possible that VEGF production can be stimulated by an LH
surge and may reflect the quality of the corpus luteum function (Geva and  Jaffe, 2000; Reynolds et al.,
2000).  In a former study (Lee et al., 1997) serum VEGF levels were significantly elevated in pregnant
patients 11-14 days after ET.  However, in our 13 pregnant patients with term deliveries the VEGF
levels in serum 12 days after ET revealed only a visual impression of higher levels than in non-
pregnant patients. This association gains further support from recent data showing significantly higher
levels of VEGF in the serum of patients on becoming pregnant (Jinno et al., 2000).  A larger IVF series
with more pregnant women is needed to confirm that VEGF in serum at time of a very early pregnancy
has significance for IVF outcome.
The facts that granulosa cells are able to accumulate and secrete in a special way VEGF, leptin
and transforming growth factor-β2 (TGFβ) (Antczak et al., 1997) which all are angiogenetic factors
(Table 3) and further, VEGF and TGFβ have been associated with gynecological malignancies
(Nakanishi et al., 1997; Donovan et al., 1997) introduced us to study the role of leptin in infertility and
its levels in serum during an IVF programme in relation to E2 levels. However, in the different types of
infertility the pretreatment luteal levels of leptin and leptin responses to IVF were similar. Thus,
circulating leptin does not appear to be involved in unexplained infertility.  The pretreatment luteal-
phase level of leptin was highly dependent on BMI, whereas the leptin responses to IVF were
independent of BMI.  During ovarian suppression, the leptin levels decreased, a phenomenon which
may be secondary to hypo-oestrogenism, as is supported by the correlations between leptin and E2
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levels prior to the treatment and at suppression. A link between leptin and E2 also gains support from
the fall in leptin following ovariectomy (Messinis et al., 1999). In addition, ovarian stimulation was
accompanied by elevation of leptin, which was probably the consequence of an oestrogen surge.
However, during ovarian hyperstimulation, no linear relationship could be demonstrated between
same-day E2 and leptin, either in our series or in other studies (Mannucci et al., 1998; Riad-Gabriel et
al., 1998; Teirmaa et al., 1998; Bützow et al., 1999).  The levels of leptin were highest at the time of
OPU, when the patients had been exposed to the effect of hMG / FSH and hCG. This may be due, in
part, to hCG, because hCG stimulates the release of leptin by the adipocytes, at least in vitro (Sivan et
al., 1998) and can perhaps cause the granulosa cells to release leptin (Antczak et al., 1997; Cioffi et al.,
1997; Karlsson et al., 1997).  Arguments against this speculation are the fall in leptin levels and the
lack of correlation between the levels of leptin and hCG at OPU and on the first days of pregnancy.
In view of the trophoblastic production of leptin (Masuzaki et al., 1997; Senaris et al., 1997) and
of the significant rises in leptin during pregnancy (Hardie et al., 1997; Sivan et al., 1998; Laivuori et
al., 2000), it was expected to see rising levels of leptin in women very early in pregnancy. It was
therefore surprising that the levels of leptin decreased during the first few days of gestation.  The higher
levels of leptin in pregnant than in non-pregnant women may be a reflection of stronger oestrogenic
stimulation (probably mediated via hCG) on leptin production from the adipocytes or of leptin
production from the granulosa cells (Kitawaki et al., 1999), or  trophoblast cells (Masuzaki et al., 1997;
Senaris et al., 1997).
Interestingly, the increases in leptin and E2 during ovarian stimulation were positively related to
successful outcome of the treatment (Figure 11). This is a novel finding and suggests that leptin may
have a role in reproduction. The leptin responses to ovarian stimulation in patients who did not become
pregnant are in accord with the finding that an increase in leptin may also be associated with a reduced
ovarian response (Bützow et al., 1999). Leptin has been detected in early human oocytes and thus may
also influence the early development of the embryo (Antczak and Van Blerkom, 1997).  It remains to
be seen, whether the leptin response to ovarian stimulation is a factor in determining the quality of the
oocyte or in angiogenesis, hence affecting endometrial receptivity or the function of the corpus luteum.
It has been shown that the endometrium of subfertile women lacks leptin receptors, in the presence of
normal concentrations of circulating hormones (Alfer et al., 2000). It is further known that leptin can
stimulate matrix metalloproteinases, which are capable of digesting the extracellular matrices of the
host tissue and hence, the increased leptin levels in the serum may reflect regulation of trophoblast
invasion in early pregnancy (Bischof et al., 2000).
2.2. ... on tumour markers in the serum
In normal cycles, the tumour marker CA 125 was significantly elevated during menstruation and in
patients with endometriosis, and these findings are in harmony with previous data (Lehtovirta et al.,
1990; Mol et al., 1998; Bon et al., 1999).  Interestingly, infertility itself appeared to have no effect on
CA 125.  It is probable that the increase in serum CA 125 in endometriosis is derived from
endometriotic tissue capable of producing CA 125 (Fedele et al., 1988). Ovarian suppression
stimulated the release of CA 125, whereas ovarian stimulation led to the return of CA 125 to baseline
level.  However, ET causes a rise in CA 125, probably from the endometrium (Weintraub et al., 1990;
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Zeimet et al., 1993).  The positive correlations of CA 125 with sex steroids and with the number of
ovarian follicles may imply that the corpora lutei also contribute to the rise in CA 125 in the luteal
phase.  Some in vitro (Zeimet et al., 1993; Paoletti et al., 1995) and in vivo (Gurgan et al., 1993;
Ozaksit et al., 1993) data support this view.  It is also possible that the OPU-associated trauma to the
peritoneum or to the ovarian surface may have contributed to the luteal rise in CA 125.  Regardless of
the cause of the rise in CA 125, it was interesting to note that 2 months´ wash-out time was insufficient
to normalize serum CA 125 levels. This may imply a prolonged effect of the IVF programme on the
synthesis and release of CA 125.  The sources of this synthesis cannot be determined from serum
measurements, although the explanatory factors may be the activation or growth of endometriotic tissue
or the healing process of multiple corpora lutei.  Clearly, longer follow-up studies are needed to
determine whether repeat IVF programmes cause cumulative increases in serum CA 125 and to reveal
the impact of a rise in CA 125 on the risk of future malignancy.
The high levels of GPHα during ovarian suppression with nafarelin are likely to result in release
of GPHα from the pituitary (Clayton, 1993).  Thus the pituitary cells maintained their capacity to
produce GPHα, although the release of LH was blocked by the GnRH agonist. A similar rise of GPHα
in the response to the GnRH agonist treatment has been reported in girls with precocious puberty
(Lahlou et al., 1987) and in patients with fibroids (Bischof et al., 1992). The falling levels of GPHα
following cessation of the GnRH agonist and injection of hCG support the stimulatory role of the
GnRH agonist on GPHα and imply that our hCG preparation contained no free GPHα.  During a
normal cycle, GPHα secretion peaked prior to LH and thus it appears probable that GPHα plays a role
in the initiation of the LH surge.  In addition, a role has been proposed for GPHα in the initiation of
decidualization of the endometrium (Nemansky et al., 1998).
2.3. ... on the risk of gynaecological malignancies
From in vitro and animal studies, it is evident that gonadotrophins and perhaps also oestrogens are
involved in the development of a number of genital cancers, especially that of breast and endometrial
cancer (Cramer and  Welch, 1983; Schiffenbauer et al., 1997; Konishi et al., 1999).  The
epidemiological data on human females also show that multiple ovulations are associated with ovarian
cancer (Webb et al., 1998), and infertility with borderline ovarian tumours that may lead to invasive
cancer (Scully, 2000).  It should, however, be noted that OPU as a part of IVF does not actually cause
multiple trauma on the ovarian surface, because the collection needle generally perforates the ovarian
surface once, and many ova can then be collected from inside the ovary.  In addition, by OPU the
follicular fluid, which is rich in growth factors and oestrogens, is thoroughly aspirated, so that the
peritoneal cavity and its organs are not exposed to it in large amounts. However, theoretically the
formation of multiple corpora lutei and their regression may lead to an increased number of inclusion
cysts and to malignant transformation.
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On the other hand, the serum concentrations of gonadotrophins are much lower (less than 20
IU/L),  during an IVF treatment than after the menopause, when the levels of FSH and LH may reach
levels exceeding 100 IU/L. Further, during the menopause women become exposed to these high levels
of gonadotrophins for up to 30 years, although these levels tend to decline in old age.  Furthermore,
during a long-protocol IVF treatment, the only gonadotrophin that is elevated is FSH, as the LH level is
depressed by the GnRH agonist, and recombinant gonadotrophins no longer contain LH.  In animal
studies, especially LH has been linked with tumour growth, owing to animals with a special genetic
predisposition (Keri et al., 2000).  Furthermore, during IVF treatment hormonal balance is optimized to
improve endometrial receptivity and thus, patients with anovulatory infertility probably favor the
maximized luteal support in terms of decreased risk of endometrial cancer (Mosgaard et al., 1997a,
Venn et al., 1999).
Since Whittemore´s study (Whittemore et al., 1992), only the study of Rossing (Rossing et al.,
1994) has been able to link ovulation inducers (long-term use of CC) with borderline and ovarian
cancer, whereas later studies point out that it is infertility, rather than the use of ovulation inducers, that
is related to ovarian cancer (Mosgaard et al., 1997b; Modan et al., 1998; Venn et al., 1999).
Interestingly the common oestrogen-associated malignancy, breast cancer, has not been associated with
infertility treatments, and the role of postmenopausal oestrogen replacement therapy in ovarian cancer
is also controversial (Coughlin et al., 2000; Rodriguez et al., 2001). On the other hand, IVF treatment
may, however, transiently increase the risk of uterine and breast cancer (Venn et al., 1999). Our finding
of persistent elevation of CA 125 at 2 month's after the IVF programme can be seen as lending support
for this hypothesis, although the source of the increased secretion of CA 125 is unknown. This may
also be supportive to the association of borderline ovarian tumours with infertility and infertility
treatments (Table 10a).
In all, it seems likely that, among infertile women, some groups (or individuals) among women
with anovulatory infertility (Modan et al., 1998) or with unexplained infertility  (Venn et al., 1999)
carry an increased risk of genital cancer.  These women may have a pre-existing malignancy in the
ovaries or the endometrium that escapes detection until ovarian stimulation with gonadotrophins and
oestrogen rise induces its growth to a detectable level. This growth may take advantage from the IVF-
induced increase in the circulating levels of special growth factors, like the angiogenetic factors VEGF
or leptin.  In addition, obese women with or without ovarian endometriosis (Brinton et al., 1997;
Zanetta et al., 2000), lean PCOS patients (Schildkraut et al., 1996) or carriers of gene mutations that
predispose to genital cancer (Nieto et al., 1999) may run an increased risk of genital malignancy,
regardless of fertility.  In cases with suspicion of a tumour during an IVF programme, it has to be
acknowledged that CA 125 and GPHα, although not TATI or hCGβ, are increased during different
phases of ovarian hyperstimulation.
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VII SUMMARY AND CONCLUSIONS
1. Between 1965-1970 and 1991-1994 the incidence of GCT in Finland fell from 0.74 / 100,000 to
0.47 / 100,000 although, at the same time, the use of CC increased 13-fold and that of gonadotrophins
200-fold.  This argues against the suggestion that ovulation inducers play an active role in the aetiology
of GCT at least in Finland.
2. Oligomenorrhea, nulliparity and anovulatory infertility were all characteristic of patients with
GCT at fertile age in 1956-1996.  GCT after the fertile age was characterized by normal parity and by
postmenopausal bleeding that frequently associated with endometrial hyperplasia or cancer.  Ovulation
inducers had been used by 5 among 41 of the patients who had been of fertile age after the introduction
of ovulation inducers.  The percentage of patients with GCT at fertile age per decade stayed constant
during the four decades.  These data suggest that GCT at fertile age may be associated with infertility,
but a causal link between the use of ovulation inducers and GCT is unlikely.
3. In the IVF group of 37 infertile women, the pretreatment midluteal serum levels of VEGF were
similar to those of the controls.  During the IVF programme the synthesis of VEGF increased at the
luteal phase, whereas during normal cycles, no cyclicity in VEGF in the serum was observed.
The serum leptin levels prior to the IVF programme, and the responses of leptin to the treatment,
were similar in 61 patients whose infertility were due to tubal occlusion, endometriosis and
unexplained infertility.  Ovarian suppression led to a fall in leptin of 21±4%, whereas the level
increased by 76±8% during ovarian stimulation paralleling the changes in serum E2 and remained
elevated in the midluteal phase of the cycle being 28±7% higher than the pretreatment concentration.
The responses of leptin and E2 during stimulation were correlated, but only in patients achieving a
clinical pregnancy.  This may imply that leptin has a role in regulating reproduction.
The elevated levels of VEGF and leptin in the serum during the luteal phase of an IVF cycle
probably reflect the increased need for angiogenesis for the function of the corpus luteum, for
endometrial maturation and for trophoblast invasion.
4. Of the tumour markers studied, prior to treatment only the serum levels of CA 125 were higher in
patients with endometriosis than in patients with tubal occlusion, unexplained infertility or no
infertility.  After the start of the GnRH analogue, the release of GPHα  increased markedly and
remained high until OPU.  Ovarian suppression was characterized by a peak in CA 125, ranging from
24 to 98% from the pretreatment level followed by a fall during ovarian stimulation. After OPU CA
125 concentrations rose significantly and remained elevated during the luteal phase (114% from
pretreatment level), regardless of the type of infertility.  This luteal phase elevation in CA 125 may
reflect simply the ovarian trauma and peritoneal irritation caused by OPU or endometrial maturation.
The serum levels of TATI or hCGβ were not affected by an IVF programme.
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By 2 months after IVF, GPHα had normalized but, in non-pregnant patients CA 125 were 12 % higher
than the pretreatment levels.  This may imply a more prolonged effect of an IVF treatment on the
secretion of CA 125 probably from physiological or endometriotic sources.  Longer follow-up studies
on IVF patients are needed to see when CA 125 normalizes after an IVF programme.
5.  Very early pregnancies, detected at 12 days after ET, did not induce marked changes in the levels of
VEGF, CA 125 or TATI in the serum when compared to non-pregnant patients.  However, the leptin
levels in sera were higher in patients with successful pregnancies than in those experiencing
miscarriages or in non-pregnant patients.  The increased synthesis of leptin in very early pregnancy
may originate from trophoblastic sources.
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